Contraceptive compounds and methods

Abstract

The present invention relates to a compound of formula (I): TIFF2024516023000078.tif37165 or a pharma- ceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein R 1 ~R 6 The present invention provides compounds, or pharma- ceutically acceptable salts, stereoisomers, solvates, or prodrugs thereof, and compositions comprising the compounds of formula (I), wherein: R has any of the values ​​described herein. These compounds are useful as contraceptives.

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No. 63 / 184,014, filed May 4, 2021, U.S. Provisional Application No. 63 / 307,943, filed February 8, 2022, and U.S. Provisional Application No. 63 / 326,524, filed April 1, 2022, the entire contents of which are incorporated herein by reference.

[0002] Statement on Federally Sponsored Research This invention was made with government support under awards HD093540 and HHSN275201300017C from the National Institutes of Health. The Government has certain rights in this invention. [Background technology]

[0003] Despite progress worldwide in providing contraceptive options to households, the rate of unintended pregnancy, defined as both unwanted and mistimed pregnancies due to non-use or incorrect / inconsistent use of contraceptives, remains high (Bearak J.,et al.,2018,Lancet Glob Health,6,e380-e389). While the rate of accidental pregnancy is decreasing, the unintended pregnancy rate remains at 45% in developed countries and 65% in developing countries (Bearak J.,et al.,2018,Lancet Glob Health,6,e380-e389). Between 2010 and 2014, approximately 56% of unintended pregnancies ended in abortion, compared with 55% in developing countries and 59% in developed countries (Bearak J.,et al.,2018,Lancet Glob Health,6,e380-e389). Therefore, there is an urgent need to increase additional approaches and resources for reversible contraception. While many reversible contraceptive methods are available for women, such as hormonal contraception, emergency contraception, vaginal rings, cervical caps, and spermicides, reversible contraception for men is limited to condoms and external ejaculation. For detailed reviews and discussions of male contraceptives, see Long JE.,et al.,2019,Clin Chem,65,53-160, and Blithe DL.,et al.,2016,Fertil Steril,106,1295-1302. There has been interest in the possible use of testosterone and various testosterone esters as contraceptives (Armory JK.,et al.,2006,Nat Clin Pract Endocrinol Metab,2,32-41,and Page ST.,et al.,2008,Endocr Rev,29,465-493), but testosterone alone does not completely suppress sperm production, and there are ethnic differences in its effectiveness (Armory JK.,et al.,2006,Nat Clin Pract Endocrinol Metab,2,32-41,and Liu PY.,et al.,2008,J Clin Endocrinol Metab,93,1774-1783).Supplementing testosterone with a progestogen enhances the suppression of sperm production at lower doses of testosterone. However, the effects of long-term exogenous testosterone administration remain unclear. Treatment with testosterone is associated with several adverse side effects, including cardiac toxicity (Xu L.,et al.,2013,BMC Medicine,11,108) and liver damage (Westaby D.,et al.,1977,Lancet,310,261-263). The most common adverse side effect was erythrocytosis, which is associated with cerebrovascular disease (Coviello AD.,et al.,2008,J Clin Endocrinol,93,914-919). In addition, exogenous testosterone has been shown to lower HDL cholesterol and increase hematocrit, hemoglobin, and thromboxane, all of which are associated with cardiovascular disease (Xu L.,et al.,2013,BMC Medicine,11,108). In addition to more serious side effects, patients also experienced weight gain, acne, pain at the injection site, and mood changes such as aggressiveness and decreased libido (World Health Organization Task Force on Methods for the Regulation of Male Fertility, 1990, Lancet, 336, 955-959). In the study mentioned above, 2.2% of patients did not reach the threshold for oligospermia, indicating that certain men are "non-responders" to testosterone treatment (World Health Organization Task Force on Methods for Regulation of Male Fertility, 1990, Lancet, 336, 955-959). Therefore, there is a need for an effective non-steroidal hormonal reversible male contraceptive with few, if any, side effects, health risks, and further complications. While hormonal therapies rely on disrupting the spermatogenic process, there are many more targets that can be pursued with non-hormonal therapies (Blithe D.,2008,Contraception,78,S23-S27). Non-hormonal male contraceptive methods target proteins that affect either sperm production or sperm function, and depending on the specificity and potency of the inhibitors against the target proteins, side effects are expected to be minimal. [Prior art documents] [Non-patent literature]

[0004] [Non-Patent Document 1] Bearak J.,et al.,2018,Lancet Glob Health,6,e380-e389 [Non-Patent Document 2] Long JE.,et al.,2019,Clin Chem,65,53-160 [Non-Patent Document 3] Blithe DL.,et al.,2016,Fertil Steril,106,1295-1302 [Non-Patent Document 4] Armory JK.,et al.,2006,Nat Clin Pract Endocrinol Metab,2,32-41 [Non-Patent Document 5] Page ST.,et al,2008,Endocr Rev,29,465-493 [Non-Patent Document 6] Liu PY.,et al.,2008,J Clin Endocrinol Metab,93,1774-1783 [Non-Patent Document 7] Xu L.,et al.,2013,BMC Medicine,11,108 [Non-Patent Document 8] Westaby D.,et al.,1977,Lancet,310,261-263 [Non-Patent Document 9] Coviello AD.,et al.,2008,J Clin Endocrinol,93,914-919 [Non-Patent Document 10] World Health Organization Task Force on Methods for the Regulation of Male Fertility,1990,Lancet,336,955-959 [Non-Patent Document 11] Blithe D.,2008,Contraception,78,S23-S27 Summary of the Invention

[0005] An effective non-steroidal hormone-based reversible male contraceptive has been identified that has few, if any, side effects, health risks, or further complications. Thus, in one aspect, the present invention provides a compound of formula (I): [ka] or a pharma- ceutically acceptable salt, stereoisomer, solvate or prodrug thereof, wherein R 1 is H, C1-C3 alkyl, or haloC1-C3 alkyl; R 2 is H, C1-C3 alkyl, or haloC1-C3 alkyl; R 3 is C6-C 10 Aryl, 5-10 membered heteroaryl, C6-C 10 aryl C1-C3 alkyl, or 5-10 membered heteroaryl C1-C3 alkyl, where any C6-C 10 Aryl, 5-10 membered heteroaryl, C6-C 10Aryl C1-C3 alkyl and 5-10 membered heteroaryl C1-C3 alkyl are halo, cyano, nitro, carboxy, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkanoyl, C1-C6 alkanoyloxy, C1-C6 alkoxycarbonyl, -NR a R b or -C(=O)NR c R d wherein any C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkanoyl, C1-C6 alkanoyloxy, and C1-C6 alkoxycarbonyl are optionally substituted with one or more groups independently selected from halo; R 4 is C6-C 10 Aryl, 5-10 membered heteroaryl, C6-C 10 aryl C1-C3 alkyl, or 5-10 membered heteroaryl C1-C3 alkyl, where any C6-C 10 Aryl, 5-10 membered heteroaryl, C6-C 10 Aryl C1-C3 alkyl and 5-10 membered heteroaryl C1-C3 alkyl are substituted with carboxy, halo, hydroxy, cyano, nitro, carboxy, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkanoyl, C1-C6 alkanoyloxy, C1-C6 alkoxycarbonyl, -NR e R f or -C(=O)NR g R h wherein any C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkanoyl, C1-C6 alkanoyloxy, and C1-C6 alkoxycarbonyl are optionally substituted with one or more groups independently selected from halo; R 5 is H, C1-C3 alkyl, hydroxy, C1-C3 alkoxy, halo, or haloC1-C3 alkyl; R 6 is H, C1-C3 alkyl, hydroxy, C1-C3 alkoxy, halo, or haloC1-C3 alkyl; Each R a and R b is independently selected from the group consisting of H, (C1-C6)alkyl, (C3-C6)cycloalkyl, (C1-C6)alkanoyl, and (C3-C6)cycloalkyl(C1-C6)alkyl, or R a and R b together with the nitrogen to which they are attached form an aziridino, azetidino, morpholino, piperazino, pyrrolidino, or piperidino ring, which is optionally substituted with one or more groups independently selected from C1-C6 alkyl and haloC1-C6 alkyl; Each R c and R d is independently selected from the group consisting of H, (C1-C6)alkyl, (C3-C6)cycloalkyl, (C1-C6)alkanoyl, and (C3-C6)cycloalkyl(C1-C6)alkyl, or R c and R d together with the nitrogen to which they are attached form an aziridino, azetidino, morpholino, piperazino, pyrrolidino, or piperidino ring, which is optionally substituted with one or more groups independently selected from C1-C6 alkyl and haloC1-C6 alkyl; Each R e and R f is independently selected from the group consisting of H, (C1-C6)alkyl, (C3-C6)cycloalkyl, (C1-C6)alkanoyl, and (C3-C6)cycloalkyl(C1-C6)alkyl, or R e and R f together with the nitrogen to which they are attached form an aziridino, azetidino, morpholino, piperazino, pyrrolidino, or piperidino ring, which is optionally substituted with one or more groups independently selected from C1-C6 alkyl and haloC1-C6 alkyl; Each R g and R h is independently selected from the group consisting of H, (C1-C6)alkyl, (C3-C6)cycloalkyl, (C1-C6)alkanoyl, and (C3-C6)cycloalkyl(C1-C6)alkyl, or Rg and R h together with the nitrogen to which they are attached form an aziridino, azetidino, morpholino, piperazino, pyrrolidino, or piperidino ring, which is optionally substituted with one or more groups independently selected from C1-C6 alkyl and haloC1-C6 alkyl; The present invention provides a retinoic acid receptor-α antagonist compound, which is a compound, or a pharma- ceutically acceptable salt, stereoisomer, solvate or prodrug thereof.

[0006] The present invention also provides a pharmaceutical composition comprising a compound of formula (I) or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.

[0007] In another embodiment, the present invention provides a method of reducing sperm count in a male subject, comprising administering to a male subject (e.g., a human) a compound of formula (I) or a pharma- ceutical acceptable salt thereof.

[0008] In another embodiment, the present invention provides a method of producing reversible infertility in a male subject, the method comprising administering to a male mammal (e.g., a human) a compound of formula (I) or a pharmaceutically acceptable salt thereof.

[0009] In another embodiment, the present invention provides a method of reducing the likelihood of conception following sexual intercourse between a male subject and a female subject, the method comprising administering a compound of formula (I) or a pharmaceutically acceptable salt thereof to the male subject (e.g., human) prior to sexual intercourse.

[0010] In another embodiment, the present invention provides a method for treating a disease or condition associated with RARα activity in a subject in which antagonism of RARα is indicated, the method comprising administering to the mammal a compound of formula (I) or a pharma- ceutically acceptable salt thereof.

[0011] In another embodiment, the present invention provides a method for selectively antagonizing RARα over RARβ and RARγ in a subject, the method comprising administering to the subject a compound of formula (I) or a pharma- ceutical acceptable salt thereof.

[0012] In another embodiment, the present invention provides a method for selectively antagonizing RARα over RARβ and RARγ, the method comprising contacting RARα, RARβ and RARγ in vitro with a compound of formula (I) or a salt thereof.

[0013] In another embodiment, the present invention provides a compound of formula (I) or a pharma- ceutically acceptable salt thereof for use in medical therapy.

[0014] In another embodiment, the present invention provides a compound of formula (I) or a pharma- ceutically acceptable salt thereof for reducing sperm count in a male subject.

[0015] In another embodiment, the present invention provides a compound of formula (I) or a pharma- ceutically acceptable salt thereof for producing reversible infertility in a male subject.

[0016] In another embodiment, the present invention provides a compound of formula (I) or a pharma- ceutically acceptable salt thereof for reducing the likelihood of conception following sexual intercourse between a male subject and a female subject.

[0017] In another embodiment, the present invention provides a compound of formula (I) or a pharma- ceutically acceptable salt thereof for the treatment of a disease or condition associated with RARα activity.

[0018] In another embodiment, the present invention provides a compound of formula (I) or a pharma- ceutically acceptable salt thereof for selectively antagonizing RARα over RARβ and RARγ in vitro.

[0019] In another embodiment, the present invention provides the use of a compound of formula (I) or a pharma- ceutically acceptable salt thereof in the preparation of a medicament for reducing sperm count in a male subject.

[0020] In another embodiment, the present invention provides the use of a compound of formula (I) or a pharma- ceutically acceptable salt thereof in the preparation of a medicament for producing reversible infertility in a male subject.

[0021] In another embodiment, the present invention provides the use of a compound of formula (I) or a pharma- ceutically acceptable salt thereof in the preparation of a medicament for reducing the likelihood of conception following sexual intercourse between a male subject and a female subject.

[0022] In another embodiment, the invention provides the use of a compound of formula (I) or a pharma- ceutically acceptable salt thereof in the preparation of a medicament for treating a disease or condition associated with RARα activity in a subject.

[0023] In another embodiment, the present invention provides the use of a compound of formula (I) or a pharma- ceutically acceptable salt thereof in the preparation of a medicament for selectively antagonizing RARα over RARβ and RARγ in a subject.

[0024] In another embodiment, the invention provides a kit comprising packaging material comprising a compound of formula (I) or a pharma- ceutically acceptable salt thereof, and instructions for using the compound of formula (I) or a pharma- ceutically acceptable salt thereof as a contraceptive (e.g., to reduce sperm count in a male subject, to cause reversible infertility in a male subject, and / or to reduce the likelihood or eliminate the likelihood of conception).

[0025] In another embodiment, the present invention provides a method for reducing sperm count in a male subject, the method comprising orally administering to a male subject (e.g., a human) a compound that is a selective antagonist of RARα, or a pharma- ceutically acceptable salt thereof.

[0026] In another embodiment, the present invention provides a method for producing reversible infertility in a male subject, the method comprising administering to a male subject (e.g., a human) a compound that is a selective RARα antagonist, or a pharma- ceutically acceptable salt thereof.

[0027] In another embodiment, the present invention provides a method for reducing the likelihood of conception following sexual intercourse between a male subject and a female subject, the method comprising administering to the male subject (e.g., human) a compound that is a selective antagonist of RARα, or a pharma- ceutically acceptable salt thereof, prior to sexual intercourse.

[0028] In another embodiment, the present invention provides a method for treating a disease or condition associated with RARα activity in a subject exhibiting antagonism of RARα, comprising administering to the subject a compound that is a selective antagonist of RARα, or a pharma- ceutically acceptable salt thereof.

[0029] In another embodiment, the present invention provides a compound, orally active, selective antagonist of RARα, or a pharma- ceutically acceptable salt thereof, for reducing sperm count in a male subject.

[0030] In another embodiment, the present invention provides a compound, or a pharma- ceutically acceptable salt thereof, which is an orally active, selective antagonist of RARα, for producing reversible infertility in a male subject.

[0031] In another embodiment, the present invention provides a compound, orally active and selective antagonist of RARα, or a pharma- ceutically acceptable salt thereof, for reducing the likelihood of conception following sexual intercourse between a male subject and a female subject.

[0032] In another embodiment, the present invention provides compounds, orally active and selective antagonists of RARα, or pharma- ceutically acceptable salts thereof, for the treatment of diseases or conditions associated with RARα activity.

[0033] In another embodiment, the invention provides the use of a compound which is an orally active, selective antagonist of RARα, or a pharma- ceutically acceptable salt thereof, in the preparation of a medicament for reducing sperm count in a male subject.

[0034] In another embodiment, the present invention provides the use of a compound that is an orally active, selective RARα antagonist, or a pharma- ceutically acceptable salt thereof, in the preparation of a medicament for producing reversible infertility in a male subject.

[0035] In another embodiment, the present invention provides the use of a compound that is an orally active, selective RARα antagonist, or a pharma- ceutically acceptable salt thereof, in the preparation of a medicament for reducing the likelihood of conception following sexual intercourse between a male subject and a female subject.

[0036] In another embodiment, the present invention provides the use of a compound that is an orally active, selective antagonist of RARα, or a pharma- ceutically acceptable salt thereof, in the preparation of a medicament for treating a disease or condition associated with RARα activity in a subject.

[0037] The present invention also provides processes and intermediates disclosed herein that are useful for preparing compounds of formula (I) or a pharma- ceutically acceptable salt, stereoisomer, solvate, or prodrug thereof. [Brief description of the drawings]

[0038] [Figure 1] 1 shows distribution data of the compound of Example 1 in Example 14. [Diagram 2] FIG. 1 shows an experimental scheme for testing the effect of the compound of Example 1 on male fertility of Example 14 (identified as GPHR-00354529). [Diagram 3] When the compound of Example 1 (identified as GPHR-00354529) was administered to male mice at 10 mg / kg for 4 weeks, it was shown from Example 16 that infertility occurred 2 weeks after administration. [Figure 4]It has been shown that when the compound of Example 1 (identified as GPHR-00354529) was administered at 20 mg / kg to male mice for two weeks, the mice became infertile four weeks after administration, as shown in Example 16. [Diagram 5] Administration of the compound of Example 1 (identified as GPHR-00354529) at 10 mg / kg to male mice for 4 weeks rendered them infertile, whereas Example 16 shows that fertility was restored 4 to 6 weeks after administration. [Figure 6] Administration of the compound of Example 1 (identified as GPHR-00354529) at 20 mg / kg to male mice for 2 weeks rendered them infertile, whereas Example 16 shows that fertility was restored 6 weeks after administration. [Figure 7] Figure 1 shows that 10 mg / kg of the compound of Example 1 reversibly reduces sperm count in mice. 25 male CD-1 mice were administered 10 mg / kg / day (gray bars) for 4 weeks. Epididymal sperm count was evaluated once a week at week 3 and compared to the control group (white bars). The mean ± SD of absolute sperm counts of 5 mice at each time point is shown. ***p<0.001, ****p<0.0001. See Example 19. [Figure 8] 7 shows that 7.5 mg / kg of the compound of Example 1 reversibly reduces sperm count in mice. Forty male CD-1 mice were administered 7.5 mg / kg / day (gray bars) for 4 weeks. Epididymal sperm count was evaluated once a week at week 3 and compared to the control group (white bars). The mean ± SD of absolute sperm counts of 10 mice at each time point is shown. ***p<0.001, ****p<0.0001. See Example 19. [Figure 9] Figure 1 shows that the compound of Example 1 does not change free serum testosterone levels in mice. Forty male CD-1 mice were administered 7.5 mg / kg / day (gray bars) for 4 weeks. Free serum testosterone levels were assessed by ELISA once a week at week 3 and compared to the control group (white bars). Mean values ​​± SD of 10 mice at each time point are shown. See Example 19. [Figure 10]Three male cynomolgus monkeys were administered the compound of Example 1 at 5 mg / kg / day for 30 days, followed by 7.5 mg / kg / day for 1 week. At day 38, animals were in recovery (ongoing). Sperm counts were assessed from fresh semen samples collected by electroejaculation at the indicated time points. Sperm counts (dark grey line with triangle, circle and diamond symbols) and mean ± SD (black line with square symbols) for each animal are shown. Horizontal dashed lines indicate reported sperm counts for non-breds. See Example 19. [Figure 11] This shows that the compound of Example 1 damages the germinal epithelium of the testis in dogs and rats. Two male beagle dogs and five male SD rats were administered 25 mg / kg / day for 14 days. On the 15th day, the animals were euthanized and organs were harvested for histopathological examination. Representative images are shown. See Example 19. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0039] The following definitions are used unless otherwise stated: halo or halogen is fluoro, chloro, bromo or iodo. Alkyl, alkoxy, etc. refer to both straight and branched chain groups, although when referring to individual radicals such as propyl, only straight chain radicals are included and branched chain isomers such as isopropyl are specifically referred to.

[0040] The term "alkyl," by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain hydrocarbon radical having the number of carbon atoms indicated (i.e., C1-8 means 1 to 8 carbons). Examples include (C1-C6) alkyl, (C1-C3) alkyl, (C2-C6) alkyl, and (C3-C6) alkyl. Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the higher homologs and isomers.

[0041] The term "alkoxy" refers to an alkyl group attached to the remainder of the molecule through an oxygen atom ("oxy").

[0042] The term "alkanoyl" refers to an alkyl group attached to the remainder of the molecule via a carbonyl C(=O)-group.

[0043] The term "cycloalkyl" refers to any saturated or partially unsaturated (non-aromatic) carbocyclic ring (i.e., (C3-C8)carbocycle) having from 3 to 8 carbon atoms. The term also includes saturated multiple condensed ring systems that are all carbon (e.g., ring systems containing 2, 3, or 4 carbocyclic rings). Thus, carbocycle includes bicyclic carbocycles (e.g., bicyclic carbocycles having about 3 to 15 carbon atoms, about 6 to 15 carbon atoms, or 6 to 12 carbon atoms, such as bicyclo[3.1.0]hexane and bicyclo[2.1.1]hexane), as well as polycyclic carbocycles (e.g., tricyclic and tetracyclic carbocycles having up to about 20 carbon atoms). The rings of multiple condensed ring systems can be connected to each other through fused, spiro, and bridged bonds, where valence requirements permit. For example, polycyclic carbocycles can be linked together through a single carbon atom to form a spiro bond (e.g., spiropentane, spiro[4,5]decane, etc.), through two adjacent carbon atoms to form a fused bond (e.g., carbocycles such as decahydronaphthalene, norsabinane, norcarane), or through two non-adjacent carbon atoms to form a bridged bond (e.g., norbornane, bicyclo[2.2.2]octane, etc.). Non-limiting examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[2.2.1]heptane, pinane, and adamantane.

[0044] The term "aryl" as used herein refers to an all-carbon aromatic monocyclic ring system or an all-carbon multiple condensed ring system in which at least one ring is aromatic. For example, in certain embodiments, an aryl group has 6-20 carbon atoms, 6-14 carbon atoms, 6-12 carbon atoms, or 6-10 carbon atoms. Aryl includes phenyl radicals. Aryl also includes multiple condensed carbocyclic ring systems (e.g., ring systems containing 2, 3, or 4 rings) having about 9-20 carbon atoms, in which at least one ring is aromatic and the other rings may or may not be aromatic (i.e., may be cycloalkyl). The rings of the multiple condensed ring system may be connected to each other via fused bonds, spiro bonds, and bridged bonds, as valence requirements permit. It is understood that the point of attachment of the multiple condensed ring system may be at any position on the ring system, including the aromatic or carbocyclic portions of the ring, as defined above. Non-limiting examples of aryl groups include, but are not limited to, phenyl, indenyl, indanyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, anthracenyl, and the like.

[0045] The term "heterocycle" refers to a saturated or partially unsaturated monocyclic ring having at least one atom other than carbon in the ring, which atom is selected from the group consisting of oxygen, nitrogen, and sulfur, and the term also includes multiple condensed ring systems having at least one such saturated or partially unsaturated ring, which are further described below. Thus, the term includes a single saturated or partially unsaturated ring (e.g., a 3-, 4-, 5-, 6-, or 7-membered ring) of about 1-6 carbon atoms and about 1-3 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur in the ring. The sulfur and nitrogen atoms may be present in their oxidized forms. Exemplary heterocycles include, but are not limited to, azetidinyl, tetrahydrofuranyl, and piperidinyl. The term "heterocycle" also includes multiple condensed ring systems (e.g., ring systems containing 2, 3, or 4 rings), where a heterocyclic monocycle (as defined above) can be fused with one or more groups selected from cycloalkyl, aryl, and heterocycle to form the multiple condensed ring system. The rings of the multiple condensed ring system can be connected to each other through fused bonds, spiro bonds, and bridged bonds, if valence requirements permit. It is understood that the individual rings of the multiple condensed ring system can be connected to each other in any order. It is also understood that the point of attachment of the multiple condensed ring system (as defined above in heterocycle) can be at any position of the multiple condensed ring system, including the heterocyclic, aryl, and carbocyclic portions of the ring. In one embodiment, the term heterocycle includes 3-15 membered heterocycles. In one embodiment, the term heterocycle includes 3-10 membered heterocycles. In one embodiment, the term heterocycle includes 3-8 membered heterocycles. In one embodiment, the term heterocycle includes 3-7 membered heterocycles. In one embodiment, the term heterocycle includes 3-6 membered heterocycles. In one embodiment, the term heterocycle includes 4-6 membered heterocycles. In one embodiment, the term heterocycle includes 3-10 membered monocyclic or bicyclic heterocycles containing 1-4 heteroatoms. In one embodiment, the term heterocycle includes 3-8 membered monocyclic or bicyclic heterocycles containing 1-3 heteroatoms.In one embodiment, the term heterocycle includes 3-6 membered monocyclic heterocycles containing 1-2 heteroatoms. In one embodiment, the term heterocycle includes 4-6 membered monocyclic heterocycles containing 1-2 heteroatoms. Exemplary heterocycles include aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, tetrahydrofuranyl, dihydrooxazolyl, tetrahydropyranyl, tetrahydrothiopyranyl, 1,2,3,4-tetrahydroquinolyl, benzoxazinyl, dihydrooxazolyl, chromanyl, 1,2-dihydropyridinyl, 2,3-dihydrobenzofuranyl, 1, These include, but are not limited to, 3-benzodioxolyl, 1,4-benzodioxanyl, spiro[cyclopropane-1,1'-isoindolinyl]-3'-one, isoindolinyl-1-one, 2-oxa-6-azaspiro[3.3]heptanyl, imidazolidin-2-one imidazolidine, pyrazolidine, butyrolactam, valerolactam, imidazolidinone, hydantoin, dioxolane, phthalimide, and 1,4-dioxane.

[0046] The term "heteroaryl" as used herein refers to a monocyclic aromatic ring having at least one atom other than carbon in the ring, which atom is selected from the group consisting of oxygen, nitrogen, and sulfur, and "heteroaryl" also includes multiple condensed ring systems having at least one such aromatic ring, which ring systems are further described below. Thus, "heteroaryl" includes a monocyclic aromatic ring of about 1-6 carbon atoms and about 1-4 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur. The sulfur and nitrogen atoms may be present in oxidized form, provided that the ring is aromatic. Exemplary heteroaryl ring systems include, but are not limited to, pyridyl, pyrimidinyl, oxazolyl, or furyl. "Heteroaryl" also includes multiple condensed ring systems (e.g., ring systems containing 2, 3, or 4 rings) in which a heteroaryl group as defined above is fused to one or more rings selected from cycloalkyl, aryl, heterocycle, and heteroaryl. It is understood that the point of attachment of a heteroaryl or heteroaryl multiple condensed ring system can be at any suitable atom of the heteroaryl or heteroaryl multiple condensed ring system, including carbon atoms and heteroatoms (e.g., nitrogen). Exemplary heteroaryls include, but are not limited to, pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazolyl, thienyl, indolyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, furyl, oxadiazolyl, thiadiazolyl, quinolyl, isoquinolyl, benzothiazolyl, benzoxazolyl, indazolyl, quinoxalyl, and quinazolyl.

[0047] The term "alkoxycarbonyl" as used herein refers to the group (alkyl)-OC(=O)-, where the term alkyl has the meaning defined herein.

[0048] The term "alkanoyloxy" as used herein refers to the group (alkyl)-C(=O)-O-, where the term alkyl has the meaning defined herein.

[0049] As used herein, the term "heteroatom" is meant to include oxygen (O), nitrogen (N), sulfur (S) and silicon (Si).

[0050] As used herein, the term "protecting group" refers to a substituent that is commonly used to block or protect a particular functional group on a compound. For example, an "amino protecting group" is a substituent added to an amino group that blocks or protects the amino functionality in the compound. Suitable amino protecting groups include acetyl, trifluoroacetyl, t-butoxycarbonyl (BOC), benzyloxycarbonyl (CBZ), and 9-fluorenylmethyleneoxycarbonyl (Fmoc). Similarly, a "hydroxy protecting group" refers to a substituent of a hydroxy group that blocks or protects the hydroxy functionality. Suitable protecting groups include acetyl and silyl. A "carboxy protecting group" refers to a substituent of a carboxy group that blocks or protects the carboxy functionality. Common carboxy protecting groups include phenylsulfonylethyl, cyanoethyl, 2-(trimethylsilyl)ethyl, 2-(trimethylsilyl)ethoxymethyl, 2-(p-toluenesulfonyl)ethyl, 2-(p-nitrophenylsulfenyl)ethyl, 2-(diphenylphosphino)-ethyl, nitroethyl, and the like. For a general description of protecting groups and their uses, see PGM Huts and T. W. Greene, Greene's Protective Groups in Organic Synthesis 4 th See, for example, U.S. Pat. No. 6,313,311, published 1999 by the American Society of Clinical Chemistry, vol. 12, no. 1, pp. 111-115, 2006.

[0051] As used herein, a wavy line intersecting a bond in a chemical structure [ka] The wavy bond indicates the point of attachment of the bond that it meets in the chemical structure to the rest of the molecule.

[0052] The terms "treat", "treatment" or "treating", insofar as it pertains to a disease or condition, include inhibiting a disease or condition, eliminating a disease or condition, and / or alleviating one or more symptoms of a disease or condition. The terms "treat", "treatment" or "treating" also refer to both therapeutic and / or prophylactic treatments or preventative measures, the purpose being to prevent or slow down (alleviate) an undesirable physiological change or disorder. For example, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, whether detectable or undetectable, attenuation of the extent of a disease or disorder, stabilization (i.e., not worsening) of the disease or disorder state, delay or slowing of disease progression, alleviation or palliative treatment of a disease state or disorder, and remission (partial or complete). "Treat", "treatment" or "treating" can also mean prolonging survival compared to expected survival in the absence of treatment. Those in need of treatment include those already with a disease or disorder, as well as those prone to having a disease or disorder, or those in need of preventing a disease or disorder. In one embodiment, "treat", "treatment" or "treating" does not include prevention or prophylaxis.

[0053] The phrase "therapeutically effective amount" or "effective amount" includes, but is not limited to, an amount of a compound that (i) treats or prevents a particular disease, condition or disorder, (ii) attenuates, ameliorates, or eliminates one or more symptoms of a particular disease, condition or disorder, or (iii) prevents or delays the onset of one or more symptoms of a particular disease, condition or disorder described herein.

[0054] The term "subject" as used herein refers to any individual or patient on whom the subject method is performed. Generally, the subject is a mammal, particularly a human, although it will be understood by those skilled in the art that the subject may be an animal. Thus, other animals are included in the definition of a subject, including vertebrates such as rodents (including mice, rats, hamsters, and guinea pigs), cats, dogs, rabbits, livestock animals (including cows, horses, goats, sheep, pigs, chickens, etc.), and primates (monkeys, chimpanzees, orangutans, and gorillas). In one embodiment, the subject is a mammal. In one embodiment, the subject is a human subject.

[0055] The term "mammal" as used herein refers to humans, higher non-human primates, rodents, livestock, cattle, horses, pigs, sheep, dogs and cats. In one embodiment, the mammal is a human.

[0056] The term "selective antagonist of RARα" refers to a compound that has at least 2-fold, 5-fold, or 10-fold greater antagonist activity at RARα compared to its activity at either RARβ or RARγ. In one embodiment, the term "selective agonist of RARα" refers to a compound that has at least 2-fold, 5-fold, or 10-fold greater antagonist activity at RARα compared to its activity at both RARβ and RARγ.

[0057] Compounds disclosed herein may also exist as tautomeric isomers in certain cases, and while only one delocalized resonance structure is depicted, all such forms are intended to be within the scope of the present invention.

[0058] The present invention also includes, but is not limited to, deuterium ( 2 It will be understood by one of skill in the art to include any of the claimed compounds that may be enriched at any or all atoms beyond the naturally occurring isotopic ratio with one or more isotopes, such as H or D. As a non-limiting example, a -CH3 group may be replaced with -CD3.

[0059] The stereochemical definitions and conventions used herein are generally in accordance with S.P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York, and Eliel, E. and Wilen, S., "Stereochemistry of Organic Compounds", John Wiley & Sons, Inc., New York, 1994. The compounds of the present invention may contain asymmetric or chiral centers and therefore exist in various stereoisomeric forms. It is intended that all stereoisomers of the compounds of the present invention, including but not limited to diastereomers, enantiomers and atropisomers, as well as mixtures thereof, including racemic mixtures, form part of the present invention. Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane-polarized light. In describing optically active compounds, the prefixes D and L, or R and S, are used to indicate the absolute configuration of the molecule around its chiral center(s). The prefixes d and l, or (+) and (-), are used to indicate the rotation of plane polarized light by the compound, with (-) or l meaning that the compound is levorotatory. Compounds with the prefix (+) or d are dextrorotatory. For a given chemical structure, these stereoisomers are identical except that they are mirror images of each other. A specific stereoisomer can also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture. A 50:50 mixture of enantiomers is called a racemic mixture or racemate, and can be found in a chemical reaction or process without stereoselectivity or stereospecificity. The terms "racemic mixture" and "racemate" refer to an equimolar mixture of two enantiomeric species that has no optical activity.

[0060] It will be apparent to those skilled in the art that the compounds of the present invention having chiral centers can exist and be isolated in optically active and racemic forms. Some compounds may exhibit polymorphism. It should be understood that the present invention includes any racemic, optically active, polymorphic or stereoisomer of the compounds of the present invention, or mixtures thereof, that have the useful properties described herein, and methods for preparing optically active forms (e.g., by recrystallization techniques, by resolution of racemic forms, by synthesis from optically active starting materials, by chiral synthesis, or by chromatographic separation using chiral stationary phases) are well known in the art.

[0061] In the formulas of compounds herein, when a bond is drawn in a non-stereochemical form (e.g., flat), the atom to which the bond is attached includes all stereochemical possibilities. In the formulas of compounds herein, when a bond is drawn in a defined stereochemical form (e.g., a thick line, a thick wedge, a dashed line, or a dashed wedge), the atom to which the stereochemical bond is attached is understood to be enriched in the absolute stereoisomer shown, unless otherwise noted. In one embodiment, the compound may be at least 51% of the absolute stereoisomer shown. In another embodiment, the compound may be at least 60% of the absolute stereoisomer shown. In another embodiment, the compound may be at least 80% of the absolute stereoisomer shown. In another embodiment, the compound may be at least 90% of the absolute stereoisomer shown. In another embodiment, the compound may be at least 95% of the absolute stereoisomer shown. In another embodiment, the compound may be at least 99% of the absolute stereoisomer shown.

[0062] The specific values ​​listed below for radicals, substituents and ranges are for illustrative purposes only and they do not exclude other defined values ​​or other values ​​within the defined ranges for radicals and substituents. It is understood that two or more values ​​can be combined. It is also understood that the values ​​listed below (or any subset thereof) can be excluded.

[0063] Specifically, (C1-C6) alkyl can be methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, pentyl, 3-pentyl, or hexyl; (C1-C6) alkoxy can be methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentoxy, 3-pentoxy, or hexyloxy; (C1-C6) alkanoyl can be acetyl, propanoyl, or butanoyl; and aryl can be aryl, aryl, or aryl. can be phenyl, indenyl, or naphthyl, and heteroaryl can be furyl, imidazolyl, triazolyl, triazinyl, oxazoyl, isoxazoyl, thiazolyl, isothiazolyl, pyrazolyl, pyrrolyl, pyrazinyl, tetrazolyl, pyridyl, (or its N-oxide), thienyl, pyrimidinyl (or its N-oxide), indolyl, isoquinolyl (or its N-oxide), or quinolyl (or its N-oxide).

[0064] R 1 A specific value for is C1-C3 alkyl.

[0065] R 1 A specific value for is methyl.

[0066] R 2 A specific value for is C1-C3 alkyl.

[0067] R 2 A specific value for is methyl.

[0068] R 3Specific values ​​of are halo, cyano, nitro, carboxy, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkanoyl, C1-C6 alkanoyloxy, C1-C6 alkoxycarbonyl, -NR a R b , and -C(=O)NR c R d C-C optionally substituted with one or more (e.g., 1, 2, 3, or 4) groups independently selected from 10 Aryl, wherein any of C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkanoyl, C1-C6 alkanoyloxy, and C1-C6 alkoxycarbonyl are optionally substituted with one or more groups independently selected from halo.

[0069] R 3 Specific values ​​of are halo, cyano, nitro, carboxy, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkanoyl, C1-C6 alkanoyloxy, C1-C6 alkoxycarbonyl, -NR a R b , and -C(=O)NR c R d wherein any of the C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkanoyl, C1-C6 alkanoyloxy, and C1-C6 alkoxycarbonyl are optionally substituted with one or more groups independently selected from halo.

[0070] R 3 A specific value for is C-C alkyl optionally substituted with one or more (e.g., 1, 2, 3, or 4) groups independently selected from C-C alkyl, optionally substituted with one or more groups independently selected from halo. 10 It is aryl.

[0071] R 3A specific value for is phenyl optionally substituted with one or more (e.g., 1, 2, 3, or 4) groups independently selected from C1-C6 alkyl, optionally substituted with one or more groups independently selected from halo.

[0072] R 3 Specific values ​​of are C6-C substituted with C1-C6 alkyl. 10 It is aryl.

[0073] R 3 A specific value for is phenyl substituted with C1-C6 alkyl.

[0074] R 3 A specific value for is 4-methylphenyl.

[0075] R 4 The specific value of is C6-C 10 Aryl, 5-10 membered heteroaryl, C6-C 10 aryl C1-C3 alkyl, or 5-10 membered heteroaryl C1-C3 alkyl, where any C6-C 10 Aryl, 5-10 membered heteroaryl, C6-C 10 Aryl C1-C3 alkyl and 5-10 membered heteroaryl C1-C3 alkyl are substituted with carboxy, halo, cyano, nitro, carboxy, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkanoyl, C1-C6 alkanoyloxy, C1-C6 alkoxycarbonyl, -NR e R f or -C(=O)NR g R h wherein any C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkanoyl, C1-C6 alkanoyloxy, and C1-C6 alkoxycarbonyl are optionally substituted with one or more groups independently selected from halo;

[0076] R 4Specific values ​​for are substituted with carboxy, further including halo, cyano, nitro, carboxy, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkanoyl, C1-C6 alkanoyloxy, C1-C6 alkoxycarbonyl, -NR a R b , and -C(=O)NR c R d C-C optionally further substituted with one or more (e.g., 1, 2, 3, or 4) groups independently selected from 10 Aryl, wherein any of C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkanoyl, C1-C6 alkanoyloxy, and C1-C6 alkoxycarbonyl are optionally substituted with one or more groups independently selected from halo.

[0077] R 4 Specific values ​​of are substituted with carboxy, halo, cyano, nitro, carboxy, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkanoyl, C1-C6 alkanoyloxy, C1-C6 alkoxycarbonyl, -NR a R b , and -C(=O)NR c R d wherein any of C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkanoyl, C1-C6 alkanoyloxy, and C1-C6 alkoxycarbonyl are optionally substituted with one or more groups independently selected from halo.

[0078] R 4 A specific value for is a C-C alkyl group substituted with carboxy, optionally further substituted with one or more (e.g., 1, 2, 3, or 4) groups independently selected from C-C alkyl, optionally substituted with one or more groups independently selected from halo. 10 It is aryl.

[0079] R 4A specific value for is phenyl substituted with carboxy and optionally further substituted with one or more (e.g., 1, 2, 3, or 4) groups independently selected from C1-C6 alkyl, which is optionally substituted with one or more groups independently selected from halo.

[0080] R 4 Specific values ​​of are C6-C substituted with carboxy. 10 It is aryl.

[0081] R 4 A specific value for is phenyl substituted with carboxy.

[0082] R 4 A specific value for is 4-carboxyphenyl.

[0083] R 5 The specific value of is H.

[0084] R 6 The specific value of is H.

[0085] Particular compounds or salts have the formula (Ia): [ka] or a pharma- ceutically acceptable salt, stereoisomer, solvate, or prodrug thereof.

[0086] A particular compound or salt has the formula (Ib): [ka] or a pharma- ceutically acceptable salt, stereoisomer, solvate, or prodrug thereof.

[0087] A particular compound or salt has the formula (Ic): [ka] or a pharma- ceutically acceptable salt, stereoisomer, solvate, or prodrug thereof.

[0088] A particular compound or salt has the formula (Id): [ka] or a pharma- ceutically acceptable salt, stereoisomer, solvate, or prodrug thereof.

[0089] The particular compound or salt is [ka] or a pharma- ceutically acceptable salt thereof.

[0090] The particular compound or salt is [ka] or a pharma- ceutically acceptable salt thereof.

[0091] A particular compound, pharma- ceutically acceptable salt, stereoisomer, solvate, or prodrug may be [ka] [ka] [ka] and pharma- ceutically acceptable salts, stereoisomers, solvates and prodrugs thereof.

[0092] Processes for preparing compounds of formula I are provided as further embodiments of the present invention and are exemplified by the following procedures, in which the meanings of the general radicals are as defined above, unless otherwise limited.

[0093] When the compound is sufficiently basic or acidic, the salt of the compound of formula I may be useful as an intermediate for isolating or purifying the compound of formula I. In addition, administration of the compound of formula I as a pharmaceutically acceptable acid or base salt may be appropriate. Examples of pharmaceutically acceptable salts include organic acid addition salts formed with acids that form physiologically acceptable anions, such as tosylate, methanesulfonate, acetate, citrate, malonate, tartrate, succinate, benzoate, ascorbate, α-ketoglutarate, and α-glycerophosphate. Also, suitable inorganic salts may be formed, including hydrochloride, sulfate, nitrate, bicarbonate, and carbonate.

[0094] Salts can be obtained using standard procedures well known in the art, for example, by reacting a sufficiently basic compound, such as an amine, with a suitable acid to give a physiologically acceptable anion. Alkali metal (e.g., sodium, potassium or lithium) or alkaline earth metal (e.g., calcium) salts of carboxylic acids can also be made.

[0095] The compound of formula (I) can be formulated as a pharmaceutical composition and administered to a mammalian host, such as a human subject, in various forms adapted to the selected route of administration, i.e., oral or parenteral administration by intravenous, intramuscular, topical or subcutaneous routes. The pharmaceutical composition of the present invention may include one or more excipients. When used in conjunction with the pharmaceutical composition of the present invention, the term "excipient" generally refers to an additional component that is combined with the compound of formula (I) or its pharma- ceutically acceptable salt to provide the corresponding composition. For example, when used in conjunction with the pharmaceutical composition of the present invention, the term "excipient" includes, but is not limited to, carriers, binders, disintegrants, lubricants, sweeteners, flavors, coatings, preservatives and dyes.

[0096] As used herein, the term "pharmaceutical composition" refers to a formulation containing an active ingredient and, optionally, a pharma- ceutically acceptable carrier, diluent or excipient. The term "active ingredient" is interchangeable with "effective ingredient" and is meant to refer to any agent capable of causing a desired effect upon administration. Examples of active ingredients include, but are not limited to, compounds, drugs, therapeutic agents, small molecules, and the like.

[0097] The pharmaceutical composition of the present invention may include one or more excipients.When used in conjunction with the pharmaceutical composition of the present invention, the term "excipient" generally refers to an additional component that is combined with the compound of formula (I) or its pharma- ceutically acceptable salt to provide the corresponding composition.For example, when used in conjunction with the pharmaceutical composition of the present invention, the term "excipient" includes, but is not limited to, carrier, binder, disintegrant, lubricant, sweetener, flavor, coating, preservative and dye.

[0098] "Pharmaceutically acceptable" means that the carrier, diluent, or excipient is compatible with the other ingredients of the formulation and is not deleterious to the recipient thereof or to the activity of the active ingredients of the formulation. Pharmaceutically acceptable carriers, excipients, or stabilizers are well known in the art and are described, for example, in Remington's Pharmaceutical Sciences, 16th edition, Osol, A. Ed. (1980). Pharmaceutically acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl, or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; serum albumin, gelatin, and the like. Examples of carriers include proteins such as glycines, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g., Zn-protein complexes); and / or non-ionic surfactants such as TWEEN®, PLURONICS®, or polyethylene glycol (PEG). Examples of carriers include, but are not limited to, liposomes, nanoparticles, ointments, micelles, microspheres, microparticles, creams, emulsions, and gels.Examples of excipients include, but are not limited to, anti-adherents such as magnesium stearate, binders such as sugars and their derivatives (sucrose, lactose, starch, cellulose, sugar alcohols, etc.), proteins such as gelatin and synthetic polymers, lubricants such as talc and silica, and preservatives such as antioxidants, vitamin A, vitamin E, vitamin C, retinyl palmitate, selenium, cysteine, methionine, citric acid, sodium sulfate, and parabens. Examples of diluents include, but are not limited to, water, alcohol, saline, glycol, mineral oil, and dimethyl sulfoxide (DMSO).

[0099] Thus, the compounds of the present invention can be administered systemically, e.g., orally, in combination with a pharma- ceutically acceptable vehicle or excipient, such as an inert diluent or an assimilable edible carrier. They can be enclosed in hard or soft shell gelatin capsules, compressed into tablets, or directly incorporated into the subject's diet. For oral therapeutic administration, the active compound may be combined with one or more pharma- ceutically acceptable excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 0.1% of the active compound. The percentage of the compositions and preparations may, of course, vary and may conveniently be from about 2 to about 60% of the weight of a given unit dosage form. The amount of active compound in such therapeutically useful compositions is such that an effective dosage level will be obtained.

[0100] Tablets, troches, pills, capsules, etc. may also contain binders such as gum tragacanth, acacia, corn starch, or gelatin, excipients such as dicalcium phosphate, disintegrating agents such as corn starch, potato starch, alginic acid, etc., lubricants such as magnesium stearate, and sweeteners such as sucrose, fructose, lactose, or aspartame, or flavorings such as peppermint, wintergreen oil, or cherry flavoring. When the unit dosage form is a capsule, in addition to the above types of materials, it may contain a liquid carrier such as vegetable oil or polyethylene glycol. Various other materials may be present as coatings or otherwise to modify the physical form of the solid unit dosage form. For example, tablets, pills, or capsules may be coated with gelatin, wax, shellac, sugar, etc. Syrup or elixir may contain active compound, sucrose or fructose as sweetener, methylparaben and propylparaben as preservatives, dye, and flavoring such as cherry flavor or orange flavor.Of course, any material used to prepare any unit dosage form must be pharmaceutically acceptable and substantially non-toxic in the amount used.In addition, active compound may be incorporated into sustained release preparations and sustained release devices.

[0101] The active compound may be administered intravenously or intraperitoneally by infusion or injection.The solution of the active compound or its salt may be prepared in water, optionally mixed with a non-toxic surfactant.Dispersions may also be prepared in glycerol, liquid polyethylene glycol, triacetin and mixtures thereof, as well as in oil.These preparations contain a preservative to prevent the growth of microorganisms under normal storage and use conditions.

[0102] Pharmaceutical dosage forms suitable for injection or infusion may include sterile aqueous solutions or dispersions containing the active ingredient, or sterile powders containing the active ingredient, adapted for extemporaneous preparation of sterile solutions or dispersions for injection or infusion, which are optionally encapsulated in liposomes. In any case, the final dosage form must be sterile, fluid, and stable under the conditions of manufacture and storage. The liquid carrier or liquid vehicle may be, for example, a solvent or liquid dispersion medium, including water, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol, etc.), vegetable oils, non-toxic glyceryl esters, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by forming liposomes, by maintaining the required particle size in the case of dispersions, or by using surfactants. The action of microorganisms can be suppressed by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers, or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

[0103] Sterile injection solutions are prepared by incorporating the active compound in the required amount in a suitable solvent with various other ingredients as listed above, if necessary, and then sterilizing by filtration. In the case of sterile powders for preparing sterile injection solutions, the preferred preparation method is vacuum drying and freeze-drying techniques, which provide a powder of the active ingredient and any additional desired ingredients present in the previously sterile-filtered solution.

[0104] For topical administration, the compounds of the invention may be applied in pure form, i.e., in a form in which the compound is a liquid, however, it will generally be desirable to administer them to the skin as a composition or formulation in combination with a dermatologically acceptable carrier, which may be a solid or liquid.

[0105] Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina, etc. Useful liquid carriers include water, alcohols or glycols, or water-alcohol / glycol blends, in which the compounds of the present invention can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants. Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize the properties for a given application. The resulting liquid composition can be applied from absorbent pads, can be used to impregnate bandages and other dressings, or can be sprayed onto the affected area using pump-type or aerosol sprays.

[0106] Also, thickening agents such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified cellulose, or modified mineral materials can be used with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like for application directly to the user's skin.

[0107] Examples of useful dermatological compositions that can be used to deliver the compounds of formula (I) to the skin are known in the art, see, for example, Jacquet et al. (U.S. Pat. No. 4,608,392), Geria (U.S. Pat. No. 4,992,478), Smith et al. (U.S. Pat. No. 4,559,157), and Wortzman (U.S. Pat. No. 4,820,508).

[0108] Useful dosages of the compounds of formula (I) can be determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; see, for example, U.S. Patent No. 4,938,949.

[0109] The amount of a compound of the invention, or an active salt or derivative thereof, required for therapeutic use will vary depending not only on the particular salt chosen, but also on the route of administration, the nature of the condition being treated, and the age and condition of the subject or patient, and will ultimately be at the discretion of the attending physician or clinician.

[0110] The dose of the compound of formula (I) administered to the subject can optionally range from about 0.0001 mg / kg to about 100 mg / kg, about 0.01 mg / kg to about 5 mg / kg, about 0.15 mg / kg to about 3 mg / kg, about 0.5 mg / kg to about 2 mg / kg, and about 1 mg / kg to about 2 mg / kg of the subject's body weight. In other embodiments, the dose can range from about 100 mg / kg to about 5 g / kg, about 500 mg / kg to about 2 mg / kg, about 750 mg / kg to about 1.5 g / kg of the subject's body weight. For example, depending on the type and severity of the disease, about 1 μg / kg to 15 mg / kg (e.g., 0.1 to 20 mg / kg) of the compound is a candidate amount to administer to the subject, whether by one or more divided doses or by continuous infusion, for example. Typical daily dosages range from about 1 μg / kg to 100 mg / kg or more, depending on the factors mentioned above. In the case of repeated administration over several days or more, depending on the condition, treatment is continued until the desired suppression of disease symptoms occurs. However, other dosing regimens may be useful. The unit dose may range from about 5 mg to 500 mg, for example, 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, etc. Specific dosage amounts include 0.1 mg, 0.5 mg, 1 mg, 1.5 mg, 2 mg, 2.5 mg, 3 mg, 3.5 mg, 4 mg, 4.5 mg, 5 mg, 5.5 mg, 6 mg, 6.5 mg, 7.0 mg, 7.5 mg, 8 mg, 8.5 mg, 9 mg, 9.5 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 7 mg, 18 mg, 19 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, and 50 mg. The progress of this therapy is monitored by conventional techniques and assays.

[0111] In some embodiments, the compound of formula (I) may be administered to a human subject in an effective amount (or dose) of less than about 1 μg / kg, for example, about 0.35 to about 0.75 μg / kg, or about 0.40 to about 0.60 μg / kg. In some embodiments, the dose of the compound is about 0.35 μg / kg, or about 0.40 μg / kg, or about 0.45 μg / kg, or about 0.50 μg / kg, or about 0.55 μg / kg, or about 0.60 μg / kg, or about 0.65 μg / kg, or about 0.70 μg / kg, or about 0.75 μg / kg, or about 0.80 μg / kg, or about 0.85 μg / kg, or about 0.90 μg / kg, or about 0.95 μg / kg, or about 1 μg / kg. In various embodiments, the absolute dose of the compound is about 2 μg / subject to about 45 μg / subject, or about 5 to about 40 μg / subject, or about 10 to about 30 μg / subject, or about 15 to about 25 μg / subject. In some embodiments, the absolute dose of the compound is about 20 μg, or about 30 μg, or about 40 μg.

[0112] In various embodiments, the dose of the compound of formula (I) can be determined by the body weight of the human subject. For example, the absolute dose of the compound may be about 2 μg for a pediatric human subject weighing about 0 to about 5 kg (e.g., about 0 kg, or about 1 kg, or about 2 kg, or about 3 kg, or about 4 kg, or about 5 kg), or about 3 μg for a pediatric human subject weighing about 6 to about 8 kg (e.g., about 6 kg, or about 7 kg, or about 8 kg), or about 5 μg for a pediatric human subject weighing about 9 to about 13 kg (e.g., about 9 kg, or about 10 kg, or about 11 kg, or about 12 kg, or about 13 kg), or about 8 μg for a pediatric human subject weighing about 14 kg to about 20 kg (e.g., about 14 kg, or about 16 kg, or about 18 kg, or about 20 kg), or about 8 μg for a pediatric human subject weighing about 21 kg to about 30 kg (e.g., about 21 kg, or about 23 kg, or about 25 kg, or about 27 kg, or about 30 kg). or about 12 μg for a pediatric human subject weighing between about 31 kg and about 33 kg (e.g., about 31 kg, or about 32 kg, or about 33 kg); or about 13 μg for an adult human subject weighing between about 34 kg and about 50 kg (e.g., about 34 kg, or about 36 kg, or about 38 kg, or about 40 kg, or about 42 kg, or about 44 kg, or about 46 kg, or about 48 kg, or about 50 kg); or about 30 μg for an adult human subject weighing between about 51 kg and about 75 kg (e.g., about 51 kg, or about 55 kg, or about 60 kg, or about 65 kg, or about 70 kg, or about 75 kg); or about 45 μg for an adult human subject weighing greater than about 114 kg (e.g., about 114 kg, or about 120 kg, or about 130 kg, or about 140 kg, or about 150 kg).

[0113] In one embodiment, the compound of formula (I) may be administered to a mammal (eg, a human) at a dose of about 7.5 mg / kg.

[0114] The desired dose may conveniently be supplied in a single dose or as multiple doses administered at appropriate intervals, for example, two, three, four or five or more sub-doses per day, which sub-doses may be further divided into a number of loosely spaced discrete administrations, for example, multiple inhalations from an insufflator or multiple drops in the eye.

[0115] As used herein, the term "fertility" or "fertility" refers to the ability to produce offspring.

[0116] As used herein, the term "infertility" or "infertility" refers to a reduced or absent ability to produce offspring. As used herein, the term "reversible infertility" refers to inducing infertility in a subject and then reversing the infertility so that the subject is fertile. The compounds disclosed herein cause reversible infertility in male subjects. While the compounds are administered, the subject becomes infertile and is unable to produce offspring. After cessation of administration of the disclosed compounds, the subject is no longer infertile and has the ability to produce offspring. In some embodiments, the infertility is determined to be due to less than 20 million sperm per milliliter, less than 19 million sperm per milliliter, less than 18 million sperm per milliliter, less than 17 million sperm per milliliter, less than 16 million sperm per milliliter, less than 15 million sperm per milliliter, less than 14 million sperm per milliliter, less than 13 million sperm per milliliter, less than 12 million sperm per milliliter, less than 110 million sperm per milliliter, or less than 120 million sperm per milliliter. In some embodiments, infertility is measured as less than 40%, less than 35%, less than 30%, less than 25%, less than 20%, less than 15%, less than 10%, less than 5%, less than 0% motility. In some embodiments, infertility is measured as less than 12% sperm with normal morphology, less than 11% sperm with normal morphology, less than 10% sperm with normal morphology, less than 9% sperm with normal morphology, less than 8% sperm with normal morphology, less than 7% sperm with normal morphology, less than 6% sperm with normal morphology, less than 5% sperm with normal morphology, less than 4% sperm with normal morphology, less than 3% sperm with normal morphology, less than 2% sperm with normal morphology, or less than 1% sperm with normal morphology.

[0117] In one embodiment, the infertility is less than 145 days, less than 140 days, less than 135 days, less than 130 days, less than 125 days, less than 120 days, less than 115 days, less than 110 days, less than 105 days, less than 100 days, less than 95 days, less than 90 days, less than 85 days, less than 80 days, less than 75 days, less than 70 days, less than 65 days, less than 60 days, less than 55 days, less than 50 days, less than 45 days, less than 40 days, less than 35 days, less than 30 days, less than 2 days after treatment. In one embodiment, infertility is achieved in less than 20 weeks, less than 19 weeks, less than 18 weeks, less than 17 weeks, less than 16 weeks, less than 15 days, less than 14 days, less than 13 days, less than 12 days, less than 11 days, less than 10 days, less than 9 days, less than 8 days, less than 7 days, less than 6 days, less than 5 days, less than 4 days, less than 3 days, less than 2 days, or less than 1 day. In one embodiment, infertility is achieved in less than 20 weeks, less than 19 weeks, less than 18 weeks, less than 17 weeks, less than 16 weeks, less than 15 weeks, less than 14 weeks, less than 13 weeks, less than 12 weeks, less than 11 weeks, less than 10 weeks, less than 9 weeks, less than 8 weeks, less than 7 weeks, less than 6 weeks, less than 5 weeks, less than 4 weeks, less than 3 weeks, less than 2 weeks, or less than 1 week.

[0118] As used herein, the term "contraceptive" refers to a method, agent, compound or device used to prevent pregnancy.

[0119] The term "disease or condition associated with RARα activity" refers to any condition that can be improved by administering a RARα-specific antagonist. Examples of such diseases and conditions include cancer, metabolic diseases, eye diseases, acne, neurodegenerative diseases and kidney diseases.

[0120] The term "disease or condition associated with RARα activity" also includes aging, depression, hyperlipidemia, vascular trauma (such as lowering serum triglycerides), ischemic injury (such as dermal tissue) and rheumatoid arthritis. In addition, the compounds of the present invention are also useful for suppressing mucin secretion, reducing the side effects of chemotherapy and radiotherapy, antidotes for retinoid poisoning, inhibiting viral (such as HIV and human cytomegalovirus) replication, antagonizing the inhibitory effect of ATRA, and rescuing BMP2-induced osteoblast formation.

[0121] The term "cancer" refers to a group of diseases characterized by abnormal and uncontrolled cell growth that begins at one site (primary site) and may invade and metastasize to other sites (secondary sites, metastases) (distinguishing cancer (malignant tumors) from benign tumors). Virtually every organ may be affected, leading to over 100 types of cancer that may affect humans. Cancer may result from many causes, including genetic predisposition, viral infection, exposure to ionizing radiation, exposure to environmental pollutants, tobacco and / or alcohol use, obesity, poor diet, lack of exercise, or a combination thereof. As used herein, "neoplasm" or "tumor," including grammatical variations thereof, means a new, abnormal growth of tissue, which may be benign or cancerous. In related embodiments, neoplasm refers to a neoplastic disease or disorder, including, but not limited to, various cancers. For example, such cancers may include prostate cancer, pancreatic cancer, biliary cancer, colon cancer, rectal cancer, liver cancer, kidney cancer, lung cancer, testicular cancer, breast cancer, ovarian cancer, pancreatic cancer, brain cancer, and head and neck cancer, melanoma, sarcoma, multiple myeloma, leukemia, lymphoma, and the like.

[0122] Metabolic disorders are disorders that adversely affect the body's processing and distribution of macronutrients such as proteins, fats, and carbohydrates. Metabolic disorders include obesity and diabetes.

[0123] Neurodegenerative diseases are a heterogeneous group of disorders characterized by progressive degeneration of the structure and function of the central or peripheral nervous system. Examples of neurodegenerative diseases include Alzheimer's disease and Parkinson's disease.

[0124] Kidney disease is a disease that damages the kidneys. Examples of kidney disease include glomerulosclerosis and polycystic kidney disease.

[0125] The invention will now be illustrated by the following non-limiting examples. EXAMPLES

[0126] General scheme for preparing compounds of formula (I) [ka]

[0127] Example 1. Synthesis of sodium 4-(5-(2,2-dimethyl-4-(p-tolyl)-2H-chromen-6-yl)-1H-pyrrol-2-yl)benzoate [ka]

[0128] a. Preparation of 6-bromo-2,2-dimethyl-4-(p-tolyl)-2H-chromene [ka]

[0129] To a solution of the ketone (8.00 g, 31.4 mmol, 1 equiv) in THF (20 mL) was added p-tolylmagnesium bromide (100 mL, 1 M in THF, 3.2 equiv) slowly over 15 min at 0 °C. The reaction mixture was slowly warmed to room temperature and stirred for 36 h. The reaction was then quenched with saturated NH4Cl solution at 0 °C and extracted with EtOAc (40 × 3 mL). The organic layer was collected, washed with brine, dried over Na2SO4, and evaporated to give a semi-solid crude product. It was then dissolved in anhydrous MeOH (60 mL) and PPTS (1.60 g, 6.37 mmol, 0.2 equiv) was added to the reaction mixture and refluxed for 4 h. The solvent was then evaporated under reduced pressure and the reaction mixture was dissolved in EtOAc:water (30 mL:30 mL) and extracted with EtOAc (30 × 3 mL). The organic layer was washed with brine, dried over Na2SO4, and evaporated to dryness. The dried residue was purified by flash column chromatography (SiO 2 , 100% hexanes to 5% EtOAc in hexanes) to give the title compound (6.89 g, 67%). 1H NMR(400 MHz,CD3OD)δ 7.31-7.27(m,5H),7.19(d,J=2.3 Hz,1H),6.82(d,J=8.5 Hz,1H),5.67(s,1H),2.45(s,3H),1.53(s,6H).

[0130] b. Preparation of 2,2-dimethyl-4-(p-tolyl)-2H-chromene-6-carbaldehyde [ka]

[0131] 6-Bromochromene (2.43 g, 7.38 mmol) was dissolved in anhydrous THF (13 mL) and the reaction mixture was cooled to -78 °C. To this n-BuLi (4.20 mL, 6.64 mmol) was added and the reaction mixture was stirred at -78 °C for 30 min. Then DMF (0.92 mL, 11.80 mmol) was added to the reaction mixture at -78 °C and the reaction was stirred at the same temperature for another 45 min. After completion of the reaction monitored by TLC, the reaction mixture was warmed to 0 °C and quenched with saturated NH4Cl solution. The aqueous layer was extracted twice with ethyl acetate. The combined organic layers were dried over Na2SO4 and the solvent was evaporated. The crude reaction mixture was purified by flash column chromatography to give the title compound as a white solid (1.1 g, 54%). 1 H NMR(400 MHz,CDCl3)δ 9.79(s,1H),7.73(dd,J=8.3,1.9 Hz,1H),7.58(d,J=2.1 Hz,1H),7.31-7.23(m,4H),7.00(d,J=8.3 Hz, 1H), 5.68 (s, 1H), 2.44 (s, 3H), 1.55 (s, 6H). 13 C NMR(100 MHz, CDCl3)δ 190.9,159.3,138.1,134.7,133.9,131.5,129.9,129.5,129.4,128.6,127.9,122.6,117.6,77.7,28.3,21.4.

[0132] c. Preparation of 1-(2,2-dimethyl-4-(p-tolyl)-2H-chromen-6-yl)prop-2-en-1-ol [ka]

[0133] The aldehyde (1 g, 3.59 mmol) was dissolved in anhydrous THF (36 mL) and the reaction mixture was cooled to -78 °C. To this was added vinylmagnesium bromide (4 mL, 3.59 mmol) and the reaction mixture was slowly warmed to -10 °C over 1 h. After complete conversion of the starting material as monitored by TLC, the reaction was quenched with a saturated solution of ammonium chloride. The aqueous layer was extracted with ethyl acetate. The combined organic layers were dried over Na2SO4 and the solvent was evaporated. The crude reaction mixture was purified by flash column chromatography to give the allylic alcohol product as a yellow viscous oil (743 mg, 67%). 1 H NMR(400 MHz,CDCl3)δ 7.27(dd,J=12.7,4.5 Hz,4H),7.19(dd,J=8.3,2.2 Hz,1H),7.07(d,J=2.1 Hz,1H),6.90(d,J=8.3 Hz,1H),6.03(ddd,J=16.6,10.3,5.8 Hz,1H),5.63(s,1H),5.30(dt,J=17.2,1.5 Hz,1H),5.17(dt,J=10.5,1.4 Hz,1H),5.08(dd,J=5.7,3.2 Hz,1H),2.44(s,3H),1.85(d,J=3.5 Hz,1H),1.51(d,J=2.2 Hz,6H). 13 C NMR(100 MHz,CDCl3)δ 153.2,140.4,137.6,135.4,134.9,134.7,136.9,133.4,130.1,128.0,127.3,124.1,122.5,117.9,114.9,76.0,75.2,27.8,27.7,21.4.

[0134] d. Preparation of 1-(2,2-dimethyl-4-(p-tolyl)-2H-chromen-6-yl)prop-2-en-1-one [ka]

[0135] To a stirred solution of chromene-allyl alcohol (70 mg, 0.23 mmol) in anhydrous dichloromethane (2 mL) was added 8 equivalents of manganese dioxide (160 mg, 1.8 mmol, activated by heating in oven for 1-2 h). The reaction was stirred at room temperature for 3 h. To this was added another batch of manganese dioxide (160 mg, 1.8 mmol) and the resulting reaction mixture was stirred for an additional 2 h after which TLC showed complete consumption of starting material. The reaction mixture was filtered through Celite® and the solvent was evaporated. The crude product was purified by flash column chromatography to give the vinyl ketone as a colorless viscous liquid (51 mg, 73%). 1 H NMR(400 MHz,CDCl3)δ 7.89(dd,J=8.5,2.1 Hz,1H),7.80 -7.76(m,1H),7.33-7.25(m,4H),7.10(dd,J=17.0,10.5 Hz,1H),6.99(d,J=8.4 Hz,1H),6.43(dd,J=17.0,1.9 Hz,1H),5.86(dd,J=10.5,1.8 Hz,1H),5.71(s,1H),2.47(s,3H),1.58(s,6H). 13 C NMR(100 MHz,CDCl3)δ 189.1,158.0,137.8,134.6,134.0,132.0,130.5,130.1,129.3,129.1,129.0,128.4,126.7,122.1,77.2,27.9,21.2.

[0136] e. Preparation of methyl 4-(4-(2,2-dimethyl-4-(p-tolyl)-2H-chromen-6-yl)-4-oxobutanoyl)benzoate [ka]

[0137] To a stirred solution of 1-(2,2-dimethyl-4-(p-tolyl)chroman-6-yl)prop-2-en-1-one (392 mg, 1.28 mmol) in DMF (4 mL) was added 3-benzyl-5-(2-hydroxyethyl)-4-methylthiazol-3-ium chloride (69.1 mg, 0.26 mmol) followed by methyl 4-formylbenzoate (210 mg, 1.28 mmol) and triethylamine (0.2 ml, 1.54 mmol). The reaction mixture was degassed for 5-10 min and heated to 80°C. Upon completion as monitored by TLC, the reaction mixture was cooled to room temperature and diluted with ethyl acetate and water. The aqueous layer was extracted twice with ethyl acetate and the combined organic layers were dried (Na2SO4) and evaporated. The crude product was purified by flash column chromatography. 1 H NMR(400 MHz,CDCl3)δ 8.16(d,J=8.1 Hz,2H),8.09(d,J=8.1 Hz,2H),7.95-7.87(m,1H),7.78(d,J=2.2 Hz,1H),7.31-7.22(m,4H),6.96(d,J=8.4 Hz,1H),5.68(s,1H),3.98(s,3H),3.44-3.38(m,2H),3.38-3.33(m,2H),2.42(s,3H),1.55(s,6H). 13 C NMR(101 MHz,CDCl3)δ 198.5,196.8,166.2,158.1,140.1,137.8,134.6,134.1,133.8,129.9,129.8,129.6, 129.3,129.0,128.4,128.0,126.1,122.0,116.8,77.1,52.4,32.8,32.1,27.9,21.2.

[0138] f. Preparation of methyl 4-(5-(2,2-dimethyl-4-(p-tolyl)-2H-chromen-6-yl)-1H-pyrrol-2-yl)benzoate [ka]

[0139] Methyl 4-(4-(2,2-dimethyl-4-(p-tolyl)-2H-chromen-6-yl)-4-oxobutanoyl)benzoate (440 mg, 0.939 mmol) was dissolved in ice-cold AcOH (16 mL) and to this was added ammonium acetate (362 mg, 4.70 mmol). The reaction mixture was refluxed at 110° C. for 18 h. After completion under TLC monitoring, the solvent was removed and the crude product was dissolved in EtOAc (50 mL) and washed with saturated aqueous sodium bicarbonate. The combined organic layers were dried (Na2SO4), evaporated and purified by flash column chromatography. 1 H NMR(400 MHz,CDCl3)δ 8.55(s,1H),8.00(d,J=8.1 Hz,2H),7.50(d,J=7.7 Hz,2H),7.36(d,J=7.6 Hz,1H),7.29(d,J=7.8 Hz,3H),7.23(d,J=7.6 Hz,3H),6.93(d,J=8.3 Hz,1H),6.65(s,1H),6.38(s,1H),5.66(s,1H),3.90(s,3H),2.42(s,3H),1.51(s,6H). 13 C NMR(101 MHz,CDCl3)δ 130.3,129.5,129.2,128.5,127.0,125.2,125.0,122.8,121.6,117.4,109.7,107.5,76.1,52.0,27.6,21.2.

[0140] g. Preparation of 4-(5-(2,2-dimethyl-4-(p-tolyl)-2H-chromen-6-yl)-1H-pyrrol-2-yl)benzoic acid [ka]

[0141] To a stirred solution of the pyrrole ester (309 mg, 0.687 mmol) in ethanol (26 ml) was added NaOH solution (20% wt / wt, 3.44 mmol) and the reaction mixture was stirred at room temperature for 48 h until complete disappearance of the starting material as monitored by TLC. The solvent was then evaporated and the reaction was acidified to pH 6-7 with 6N HCl. The aqueous layer was extracted with ethyl acetate (2×50 ml) and then with dichloromethane (2×50 ml). The combined organic layers were dried (Na2SO4) and the solvent was evaporated. The crude product was purified by flash column chromatography to give the title compound as a yellow solid (230 mg, 76%). 1 H NMR(400 MHz,CD3OD)δ 7.96(d,J=8.2 Hz,2H),7.68(d,J=8.2 Hz,2H),7.51(dd,J=8.3,2.2 Hz,1H),7.35-7.16(m,5H),6.88(d,J=8.4 Hz,1H),6.63(d,J=3.6 Hz,1H),6.25(d,J=3.7 Hz,1H),5.68(s,1H),2.40(s,3H),1.48(s,6H). 13 C NMR(100MHz,CD3OD)δ 169.9,153.7,138.9,138.8,136.8,136.6,136.1,132.9,131.3,130.3,130.2,129. 7,128.0,127.2,126.6,124.1,123.9,123.1,118.1,110.5,108.0,76.9,27.7,21.3.

[0142] h. Preparation of sodium 4-(5-(2,2-dimethyl-4-(p-tolyl)-2H-chromen-6-yl)-1H-pyrrol-2-yl)benzoate [ka]

[0143] To a stirred solution of the acid in methanol was added 1M aqueous NaOH dropwise and the resulting mixture was stirred at room temperature for 30 min. The solvent was evaporated and the crude reaction mixture was co-evaporated with toluene (3 times) to remove traces of water. The solid was further washed with 5% aqueous acetone to remove inorganic impurities and then evaporated to dryness to give the sodium salt as a yellow solid (quantitative yield). 1 H NMR(400 MHz,CD3OD)δ 7.91(d,J=8.1 Hz,2H),7.59(d,J=8.2 Hz,2H),7.51(dd,J=8.4,2.2 Hz,1H),7.29(d,J=7.6 Hz,5H),6.87(d,J=8.4 Hz,1H),6.53(d,J=3.6 Hz,1H),6.22(d,J=3.6 Hz,1H),5.69(s,1H),2.42(s,3H),1.49(s,6H).13C NMR(100 MHz,CD3OD)δ 175.6,153.4,138.8,136.8,136.3,136.2,135.8,135.6,133.8,130.8(2C),130.2,130.1(2C),1 29.7(2C),127.5,126.4,123.9,123.9,123.0,118.1,109.0,108.9,107.6,76.9,27.7(2C),21.3.

[0144] Example 2. Alternative synthesis of representative compounds of formula (I) [ka]

[0145] a. Preparation of tert-butyl 2-(4-(methoxycarbonyl)phenyl)-1H-pyrrole-1-carboxylate [ka]

[0146] Aryl halide (17.00 g, 79.05 mmol, 1 equiv) and 1-boc-pyrrole-5-boronic acid (20.00 g, 94.78 mmol, 1.2 equiv) were placed in a round bottom flask, followed by the addition of THF (190 mL) and aqueous K3PO4 (0.5 M, 380 mL, 2.4 equiv). The reaction mixture was sparged with nitrogen gas for 15 min, followed by the addition of XPhos Pd G2 (1.50 g, 1.91 mmol, 0.024 equiv). The flask was then placed in a preheated oil bath at 45 °C and stirred for 5 h. After completion of the reaction, brine was added and the mixture was extracted with EtOAc (50 mL × 3) and dried over MgSO4. The solvent was evaporated to dryness. The residue was purified by flash column chromatography (SiO 2 , 100% hexanes to 20% EtOAc in hexanes) to give the coupled product as a white solid (22.142 g, 93%). 1 H NMR(400 MHz,CDCl3)δ 8.06-7.98(m,2H),7.45-7.35(m,3H),6.29-6.21(m,2H),3.93(s,3H),1.37(s,9H). 13 C NMR (100 MHz, CDCl3) δ 167.1, 149.3, 139.1, 134.1, 129.1, 128.7, 123.6, 115.6, 111.0, 84.2, 52.2, 27.8. This compound is also commercially available.

[0147] b. Preparation of methyl 4-(1H-pyrrol-2-yl)benzoate [ka]

[0148] The product from step a (18.13 g, 60.16 mmol, 1 equiv.) was dissolved in THF (60 mL) and NaOMe (80 mL, 25 wt.% in MeOH, 6 equiv.) was added. The mixture was stirred for 5 min and quenched with saturated NH4Cl solution. The resulting mixture was extracted with dichloromethane (50 mL x 3), the organic phase was dried over MgSO4 and evaporated to dryness to give the deprotected product as a white solid (11.615 g, 96%). 1H NMR(400 MHz,CDCl3)δ 8.62(s,1H),8.09-8.01(m,2H),7.59-7.51(m,2H),6.95(td,J=2.7,1.4 Hz,1H),6.69(ddd,J=3.8,2.7,1.4 Hz,1H),6.36(dt,J=3.7,2.6 Hz,1H),3.94(s,3H). 13 C NMR(100 MHz,CDCl3)δ 166.9,136.8,131.0,130.4,127.3,123.1,120.3,110.7,108.0,52.1.

[0149] c. Preparation of methyl 4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrol-2-yl)benzoate [ka]

[0150] The product from step b (12.00 g, 59.63 mmol, 1 equiv.), B2Pin2 (8.304 g, 32.7 mmol, 0.55 equiv.), [Ir(COD)OMe] (0.60 g, 0.91 mmol, 0.015 equiv.), and 4,4'-dtbpy (0.484 g, 1.80 mmol, 0.03 equiv.) were combined in a round-bottom flask, evacuated under vacuum, and purged with nitrogen. This process was repeated three times before mixing with hexanes (120 mL). The suspension was refluxed under nitrogen for 6 h. After 6 h, the reaction mixture was solubilized in DCM and a silica gel slurry was prepared for flash chromatography (SiO, 100% hexanes to 20% EtOAc in hexanes) to give the pyrrole boronic acid product as an off-white solid (16.71 g, 86%). 1 H NMR(400 MHz,CDCl3)δ 8.99(s,1H),8.07-8.00(m,2H),7.63-7.56(m,2H),6.89(dd,J=3.7,2.4 Hz,1H),6.69(dd,J=3.7,2.5 Hz,1H),3.92(s,3H),1.34(s,12H). 13C NMR(101 MHz,CDCl3)δ 167.0,136.4,135.6,130.5,128.2,124.0,122.1,109.3,84.1,52.2,24.9.

[0151] d. Preparation of 6-bromo-2,2-dimethyl-4-(p-tolyl)-2H-chromene [ka]

[0152] To a solution of bromochromone (8.00 g, 31.4 mmol, 1 equiv) in THF (20 mL) was added p-tolylmagnesium bromide (100 mL, 1 M in THF, 3.2 equiv) slowly over 15 min at 0 °C. The reaction mixture was slowly warmed to room temperature and stirred for 36 h. The reaction was quenched with saturated NH4Cl solution at 0 °C and extracted with EtOAc (40 x 3 mL). The organic layers were collected, washed with brine, dried over MgSO4, and evaporated to give a semi-solid crude product. The semi-solid crude product was dissolved in anhydrous MeOH (60 mL) and PPTS (1.60 g, 6.37 mmol, 0.2 equiv) was added. The resulting mixture was refluxed for 4 h. The solvent was evaporated under reduced pressure and the resulting material was dissolved in EtOAc:water (30 mL:30 mL) and extracted with EtOAc (30 x 3 mL). The combined organic layers were washed with brine, dried over MgSO4, and evaporated to dryness. The residue was purified by flash column chromatography (SiO 2 , 100% hexanes to 5% EtOAc in hexanes) to give the bromochromene product (6.89 g, 67%) which was a colorless liquid that became solid when frozen. 1 H NMR(400 MHz,CD3OD)δ7.31-7.27(m,5H),7.19(d,J=2.3 Hz,1H),6.82(d,J=8.5 Hz,1H),5.67(s,1H),2.45(s,3H),1.53(s,6H). 13 C NMR(100 MHz,CD3OD)152.5,137.8,134.8,133.9,131.8,129.8,129.3,128.5,128.2,124.5,118.7,112.8,76.2,27.6,21.3.

[0153] e. Preparation of methyl 4-(5-(2,2-dimethyl-4-(p-tolyl)-2H-chromen-6-yl)-1H-pyrrol-2-yl)benzoate [ka]

[0154] The bromochromene from step d (580 mg, 1.76 mmol, 1 equiv) and the pyrrole boronate from step c (630 mg, 1.93 mmol, 1.1 equiv) were combined in a vial and dissolved in THF (3.5 mL), and an aqueous solution of K3PO4 (0.5 M, 7 mL, 2.0 equiv) was added. The reaction mixture was sparged with nitrogen gas for 15 min, followed by the addition of XPhos Pd G2 (0.035 g, 0.04 mmol, 0.025 equiv). The mixture was placed in a preheated oil bath at 45 °C and stirred for 3 h. After the reaction was complete, brine was added and the resulting mixture was extracted with EtOAc (50 mL × 3). The combined organics were dried over MgSO4 and evaporated to dryness. The residue was purified by flash column chromatography (SiO2, 100% hexane to 20% EtOAc in hexane) to give the chromene ester product as a bright yellow solid (681 g, 86%).

[0155] f. Preparation of 4-(5-(2,2-dimethyl-4-(p-tolyl)-2H-chromen-6-yl)-1H-pyrrol-2-yl)benzoic acid [ka]

[0156] To a solution of the chromene ester product (600 mg, 1.33 mmol, 1 equiv) in THF (10 mL) and MeOH (10 mL) was added LiOH (280 mg, 6.67 mmol, 5 equiv) dissolved in water (10 mL), and the resulting mixture was stirred at room temperature for 20 h. The organic layer was evaporated under reduced pressure, and the aqueous suspension was acidified to pH 1.0 with 2N HCl. The mixture was then extracted with EtOAc (10 mL x 3), washed with brine, and dried over MgSO4. The extract was purified by flash column chromatography (SiO2, 100% hexane to 50% EtOAc in hexane, 2% HCOOH) to give the acid (526 mg, 91%) as a yellow solid.

[0157] Example 3 Sodium 4-(5-(2,2-dimethyl-4-(p-tolyl)-2H-chromen-6-yl)-1H-pyrrol-2-yl)-2-fluorobenzoate [ka]

[0158] a. Preparation of methyl 2-fluoro-4-(1H-pyrrol-2-yl)benzoate [ka]

[0159] To a stirred solution of 1H-pyrrole (230 mg, 238 μL, 4 equiv, 3.43 mmol) in N,N-dimethylacetamide (3 mL, 0.3 mol) was added palladium(II) acetate (9.63 mg, 0.05 equiv, 42.9 μmol), potassium acetate (168 mg, 2 equiv, 1.72 mmol), and methyl 4-bromo-2-fluorobenzoate (200 mg, 1 equiv, 858 μmol). The solution was degassed using nitrogen for 15 min. The resulting solution was heated at 150° C. in a sealed tube for 36 h. The reaction mixture was directly purified by flash column chromatography to give the title compound (150 mg, 80%). 1H NMR(400 MHz,CDCl3)δ 8.59(s,1H),7.93(t,J=8.0 Hz,1H),7.28(dd,J=8.3,1.7 Hz,1H),7.20(dd,J=12.2,1.8 Hz,1H),6.94(td,J=2.7,1.3 Hz,1H),6.67(dq,J=3.8,1.6 Hz,1H),6.34(q,J=2.8 Hz,1H),3.93(s,3H).

[0160] b. Preparation of methyl 2-fluoro-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrol-2-yl)benzoate [ka]

[0161] To a solution of methyl 2-fluoro-4-(1H-pyrrol-2-yl)benzoate (141 mg, 1 equiv, 0.643 mmol) in anhydrous n-hexane (5.88 mL, 0.170 mol), 4,4'-di-tert-butyl-2,2'-bipyridine (5.18 mg, 0.030 equiv, 19.3 μmol), bis(pinacolato)diboron (163 mg, 1 equiv, 643 μmol), and (1,5-cyclooctadiene)(methoxy)iridium(I) dimer (6.39 mg, 0.015 equiv, 9.64 μmol) were added. The resulting mixture (not homogeneous) was heated to reflux and stirred for 1.5 hours (within 1 hour of heating, the reaction color changes to dark brown and the reaction mixture becomes homogeneous). The crude mixture was then evaporated and purified directly by flash column chromatography to give the title compound (142 mg, 64%). 1 H NMR(400 MHz,CDCl3)δ 9.13(s,1H),7.96(t,J=7.9 Hz,1H),7.37(dd,J=8.3,1.7 Hz,1H),7.30(dd,J=12.3,1.6 Hz,1H),6.90(dd,J=3.7,2.3 Hz,1H),6.71(dd,J=3.7,2.5 Hz,1H),3.95(s,3H),1.36(s,12H).

[0162] c. Preparation of 6-iodo-2,2-dimethylchroman-4-one [ka]

[0163] To a solution of 1-(2-hydroxy-5-iodophenyl)ethan-1-one (2.00 g, 1 eq, 7.63 mmol) in methanol (40.0 mL, 0.19 mol, 1.0 eq, 7.6 mmol) was added pyrrolidine (847 mg, 0.98 mL, 1.56 eq, 11.9 mmol) and acetone (678 mg, 0.86 mL, 1.53 eq, 11.7 mmol). The reaction mixture was stirred overnight. TLC showed complete consumption of starting material. MeOH was evaporated and the crude mixture was washed with 1N HCl (aq) and extracted with EtOAc. The crude reaction mixture was dried over Na2SO4 and evaporated. The resulting residue was purified by flash column chromatography (silica gel, hexanes / ethyl acetate, 100:00 to 70:30) to give the title compound (1.86 g, 81%, brown oil). 1 H NMR(400 MHz,CDCl3)δ 8.12(d,J=2.3 Hz,1H),7.68(dd,J=8.7,2.3 Hz,1H),6.69(d,J=8.7 Hz,1H),2.69(s,2H),1.43(s,6H). 13 C NMR(100 MHz,CDCl3)δ 191.1,159.6,144.4,135.2,122.1,120.9,82.9,79.7,48.5,26.6.

[0164] d. Preparation of 6-iodo-2,2-dimethyl-4-(p-tolyl)-2H-chromene [ka]

[0165] The title compound was prepared following the procedure described for the bromo analog (55% off-white solid). 1H NMR(400 MHz,CDCl3)7.47(dd,J=8.5,2.2 Hz,1H),7.34(d,J=2.2 Hz,1H),7.26(s,4H),6.70(d,J=8.5 Hz,1H),5.64(s,1H),2.45(s,3H),1.52(s,6H).

[0166] e. Preparation of methyl 4-(5-(2,2-dimethyl-4-(p-tolyl)-2H-chromen-6-yl)-1H-pyrrol-2-yl)-2-fluorobenzoate [ka]

[0167] A mixture of 6-iodo-2,2-dimethyl-4-(p-tolyl)-2H-chromene (154 mg, 1 equiv., 0.408 mmol) and methyl 2-fluoro-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrol-2-yl)benzoate (141 mg, 1 equiv., 0.033 mol) in 1,4-dioxane (12.36 mL, 0.033 mol) and water (1.24 mL, 0.33 mol) was added. g, 1.00 equiv, 0.408 mmol), sodium carbonate (303 mg, 7 equiv, 2.86 mmol), diacetoxypalladium (14.7 mg, 0.160 equiv, 0.0653 mmol) and dicyclohexyl(2',4',6'-triisopropyl-[1,1'-biphenyl]-2-yl)phosphane (97.3 mg, 0.500 equiv, 0.204 mmol) were added. The resulting solution was degassed with N2 gas for 15 min. The reaction mixture was then refluxed at 100 °C for 16 h. The crude reaction mixture was evaporated to dryness and purified by flash column chromatography to give the title compound (149 mg, 78%). 1H NMR(400 MHz,CDCl3)δ 8.75(s,1H),7.81(t,J=8.0 Hz,1H),7.30(dd,J= 8.4,2.2 Hz,1H),7.23-7.10(m,7H),6.84(d,J=8.3 Hz,1H),6.57(t,J=3.2 Hz,1H),6.33-6.25(m,1H),5.57(s,1H),3.83(s,3H),2.33(s,3H),1.43(s,6H).

[0168] f. Preparation of sodium 4-(5-(2,2-dimethyl-4-(p-tolyl)-2H-chromen-6-yl)-1H-pyrrol-2-yl)-2-fluorobenzoate [ka]

[0169] To a stirred solution of the pyrrole ester (97 mg, 0.21 mmol) in ethanol (2.0 mL), aqueous sodium hydroxide (5 M, 1 mmol) was added and the reaction mixture was stirred at room temperature for 48 h until complete disappearance of the starting material while being monitored by TLC. The solvent was then evaporated and the reaction was acidified to pH 6-7 with 6 N HCl. The aqueous layer was extracted with ethyl acetate (2 x 10 ml) and then with dichloromethane (2 x 10 mL). The combined organic layers were dried over sodium sulfate and the solvent was evaporated to give the acid (47 mg, 50%). To a stirred solution of the acid (20 mg, 44 mmol) dissolved in anhydrous MeOH (0.44 mL), sodium hydroxide (1 M, 40 mL) was added and the resulting mixture was stirred at room temperature for 30 min. The solvent was evaporated and the crude reaction mixture was co-evaporated with toluene (3 times) to remove traces of water. The crude solid was purified by reverse phase column chromatography to give the title compound (quantitative yield). 1H NMR(400 MHz,MeOD)δ 7.64(t,J=8.0 Hz,1H),7.49(dd,J=8.3,2.2 Hz,1H),7.38-7.32(m,1H),7.28(d,J=12.4 Hz,5H),6.86(d,J=8.4 Hz,1H),6.53(d,J=3.6 Hz,1H),6.21(d,J=3.6 Hz,1H),5.68(s,1H),2.40(s,3H),1.48(s,6H).

[0170] Example 4 Sodium 4-(5-(2,2-dimethyl-4-(p-tolyl)-2H-chromen-6-yl)-1H-pyrrol-2-yl)-2,6-difluorobenzoate [ka]

[0171] a. Preparation of methyl 2,6-difluoro-4-(1H-pyrrol-2-yl)benzoate [ka]

[0172] Methyl 4-bromo-2,6-difluorobenzoate (300.00 mg, 1 equiv., 1.1951 mmol) and 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrole (576.77 mg, 2.5 equiv., 2.9877 mmol) in 1,4-dioxane (36.2 mL, 0.033 mol) and water (3.62 mL, 0.330 mol). To a mixture of 1,2-dichlorophenyl ether (1,2-dichlorophenyl ether), sodium carbonate (886.66 mg, 7 equiv, 8.37 mmol), diacetoxypalladium (42.93 mg, 0.16 equiv, 191.21 μmol), and Xphos (dicyclohexyl(2',4',6'-triisopropyl-[1,1'-biphenyl]-2-yl)phosphane) (284.9 mg, 0.5 equiv, 597.5 μmol) were added. The resulting solution was degassed with N2 gas for 15 min. The reaction mixture was then refluxed at 100 °C for 16 h. The crude reaction mixture was evaporated to dryness and purified by flash column chromatography to give the title compound (181 mg, 64%) as a white solid. 1 H NMR(400 MHz,CDCl3)δ 9.93(s,1H),7.10-7.01(m,2H),6.89(td,J=2.8,1.4 Hz,1H),6.61(ddd,J=3.9,2.6,1.4 Hz,1H),6.26(dt,J=3.7,2.5 Hz,1H),3.90(s,3H).

[0173] b. Preparation of methyl 2,6-difluoro-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrol-2-yl)benzoate [ka]

[0174] The title compound (234 mg, 60%) was prepared following the procedure described for its monofluoro analogue. 1 H NMR(400 MHz,CDCl3)δ 9.06(s,1H),7.12-7.05(m,2H),6.86(dd,J=3.7,2.3 Hz,1H),6.66(dd,J=3.7,2.5 Hz,1H),3.94(s,3H),1.33(s,12H).

[0175] c. Preparation of methyl 4-(5-(2,2-dimethyl-4-(p-tolyl)-2H-chromen-6-yl)-1H-pyrrol-2-yl)-2,6-difluorobenzoate [ka]

[0176] The title compound was prepared similarly to the procedure described in Example 3, subpart e (33 mg, 80%). 1 H NMR(400 MHz,CDCl3)δ 8.59(s,1H),7.41-7.34(m,1H),7.27(dt,J=13.4,6.8 Hz,5H),7.01(d,J=10.1 Hz,2H),6.95(d,J=8.3 Hz,1H),6.65(t,J=3.2 Hz,1H),6.40(d,J=3.2 Hz,1H),5.68(s,1H),3.94(s,3H),2.44(s,3H),1.53(s,6H).

[0177] d. Preparation of sodium 4-(5-(2,2-dimethyl-4-(p-tolyl)-2H-chromen-6-yl)-1H-pyrrol-2-yl)-2,6-difluorobenzoate [ka]

[0178] The title compound was prepared similarly to the procedure described in Example 3, subpart f (68 mg, 69%). 1 H NMR(400 MHz,MeOD)δ 7.49(dd,J=8.4,2.2 Hz,1H),7.32-7.23(m,5H),7.17(d,J=8.6 Hz,2H),6.87(d,J=8.3 Hz,1H),6.53(d,J=3.7 Hz,1H),6.21(d,J=3.7 Hz,1H),5.68(s,1H),2.40(s,3H),1.48(s,6H).

[0179] Example 5. Metabolic Stability Assay The metabolic stability of the compound of Example 1 was evaluated using standard assay protocols and the results are shown in the table below. [Table 5]

[0180] Example 6. Stability in mouse and human hepatocytes The metabolic stability of the compound of Example 1 was evaluated in mouse and human hepatocytes using standard assay protocols, and the results are shown in the table below. [Table 6]

[0181] Example 7. Calculation of LogD The LogD of the compound of Example 1 and progesterone were measured using standard assay protocols and the results are shown in the table below. [Table 7]

[0182] Example 8. Solubility Measurement The stability of the compound of Example 1 and progesterone in PBS pH 7.4 was measured using a standard assay protocol, and the results are shown in the table below. [Table 8]

[0183] Example 9. hERG Assay Potential inhibitory effect on human Ether-a-go-go related gene (hERG) channel was evaluated using manual patch clamp system. HEK293 cell line stably transfected with hERG gene was used. Dofetilide was used as positive control. Results are shown in the following table. From this data, compound of Example 1 is ranked as a weak inhibitor on hERG channel. [Table 9]

[0184] Example 10. Mini Ames Assay The compound of Example 1 was evaluated in the Mini Ames assay and the results were negative.

[0185] Example 11. HepG2 and human liver fibroblast assays The compound of Example 1 was evaluated in a HepG2 cytotoxicity assay, with negative results.

[0186] Example 12. Human liver fibroblast assay The compound of Example 1 was evaluated in the human liver fibroblast assay with negative results.

[0187] The data for Examples 5-12 are summarized below.

[0188] In Vitro Assay Overview Metabolic stability (mouse): 86% after 1 hour · Metabolic stability (human): 100% after 1 hour, t 1 / 2 -570 minutes Log D=3.5 Solubility: 2mg / ml (saline) · hERG (negative, >30μm) · Mini Ames (negative) HepG2 cytotoxicity assay (negative) Human lung fibroblast test (negative)

[0189] Example 13. Transactivation Assay On each 384-well plate, a dose response of the agonist, 9-cis-retinoic acid (9-cis-RA) for RARα, all-trans-retinoic acid (ATRA) for RARβ and γ, and the reference antagonists BMS-189453 or BMS-189532 were included. Control wells containing cells with no added agonist defined the background signal value. EC50 in DMSO was dispensed using an echo acoustic nanolight dispenser (Labcyte, San Jose, CA). 80 Concentrations of agonists (180 nM 9-cis-RA for RARα, 8 nM ATRA for RARβ and γ) were added to control and compound wells. The compound of Example 1 and reference compound in DMSO (0.4% final) were added to the plate in triplicate in an 8-point dose response using an Echo. Cell suspension (30 μL) was added to each well and the assay plate was incubated overnight at 37° C. in a 5% CO2 incubator. Luciferase detection reagent (15 μL) was then added and the plate was incubated at room temperature for 30 minutes. Luminescence was quantified using an EnSpire plate reader (PerkinElmer, Waltham, MA). IC 50 Values ​​were determined by fitting the dose-response data with a four-parameter logistic equation in GraphPad Prism 7.0. The resulting data are shown below. I C 50 RARα=6.8nM I C 50 RARβ=>3700nM I C 50 RARγ=>3700nM

[0190] Example 14. Distribution Assay Thirty CD-1 mice were orally dosed with 10 mg / kg of the compound of Example 1. At the indicated time points (5, 15, 30 min and 1, 2, 4, 8, 16, 24, 48 h), animals in groups of three were bled and euthanized. Testes and brains were then harvested. Resulting plasma and tissues were frozen at <-20°C until analysis by LC / MS / MS. Peak levels in plasma were approximately 2.1 μM 15 min after dosing, plateaued at approximately 1.5 μM between 30 min and 8 h, and were still detectable after 48 h (12.9 nM). The data obtained are shown in Figure 1.

[0191] Example 15. Effects on male infertility To investigate the effect of the compound of Example 1 on male infertility, a study was conducted on male mice. Mice were rendered infertile by treatment with 10 mg / kg per day for 4 weeks or 20 mg / kg per day for 2 weeks (Figure 2). Fertility was restored after cessation of compound treatment.

[0192] Example 16. Mating studies using embryo numbers Mating studies using embryo numbers were performed as described by Chung, SS; Wang, X.; Roberts, SS; Griffey, SM; Reczek, PR; Wolgemuth, DJ. Oral administration of retinoic acid receptor antagonists reversibly inhibits spermatogenesis in mice. Endocrinology 2011, 152, 2492-2502. The data show that infertility was induced in male mice by administration of the compound of Example 1 at a dose of 10 mg / kg per day for 4 weeks or at a dose of 20 mg / kg per day for 2 weeks (Figures 3 and 4). These experiments also showed that the induction of infertility was reversible. Figure 5 shows that infertility induced in male mice administered the compound of Example 1 at 10 mg / kg / day for 4 weeks was reversed 4-6 weeks after the compound was discontinued. FIG. 6 shows that infertility induced in male mice treated with the compound of Example 1 at 20 mg / kg / day for two weeks was reversed six weeks after administration of the compound was discontinued.

[0193] Example 17. Representative pharmaceutical dosage forms Representative pharmaceutical dosage forms containing a compound of formula (I) ("Compound X") for therapeutic or prophylactic use in humans are illustrated below. [Table 10-1] [Table 10-2]

[0194] The above formulations may be prepared using conventional procedures well known in the pharmaceutical art.

[0195] Example 18. Safety Profile Introduction and Objectives: Men lack contraceptive options that meet their needs and lifestyles. The compound of Example 1 acts as a retinoic acid receptor (RAR)-α antagonist, thus inhibiting both spermatogenesis and spermatogenesis. The compound of Example 1 showed 99% contraceptive efficacy and complete reversibility at 10 mg / kg in mice, and a significant reduction in sperm count at 7.5 mg / kg.

[0196] Methods: The safety profile of the compound of Example 1 was evaluated in vitro by target selectivity (cell-based luciferase assay), off-target screening (e.g. patch clamp and cAMP assay) and genotoxicity (Ames test) studies. Acute toxicity in animals was investigated in single-dose studies in mice, rats and dogs. Dose-ranging (DRF) studies were conducted in rats and dogs to evaluate subchronic toxicity over a 14-day dosing period.

[0197] Results: The compound of Example 1 has high selectivity for RAR-α (respective IC 50 6.7 nM for RAR-α and >3,700 nM for RAR-β and RAR-γ), and were not considered hERG inhibitors (IC 50It is not potentially genotoxic (negative Ames test) and has no clinical efficacy in mice (>30 μM) and no clinical efficacy in rats (>30 μM) (>30 μM) (>30 μM) and no clinical efficacy in mice (>30 μM) ...

[0198] Conclusion: The compound of Example 1 demonstrated potent and reversible efficacy in mice and an initial safety profile with at least a 10-fold safety margin in rats and dogs.

[0199] Example 19. In vivo test for infertility recovery Mouse study with sperm count as a readout: In the first study, 25 sexually mature male CD-1 mice were dosed at 10 mg / kg / day for 4 weeks, with epididymal sperm counts assessed 24 hours after the final dose of 0.51 ± 0.27 × 10 7 Dosing was stopped on day 29. Sperm counts began to increase over the remaining 2 weeks, supporting the reversibility of the effect (Figure 7). Study 2: A subsequent efficacy study was performed using 7.5 mg / kg of the compound of Example 1 to determine the minimal effective dose in mice. Forty sexually mature male CD-1 mice were dosed at 7.5 mg / kg / day for 4 weeks, resulting in an 86% reduction in epididymal sperm counts, assessed 24 hours after the last dose, of 0.82±0.45×10 7 Dosing was stopped on day 29. Sperm counts began to increase over the remaining 2 weeks, supporting the reversibility of the effect (Figure 8). Free serum testosterone concentrations were also measured in animals treated with 7.5 mg / kg / day. Free testosterone levels did not change significantly in treated animals during either the treatment or recovery periods compared to control animals (Figure 9).

[0200] Cynomolgus monkey study with sperm concentration as readout: The study design contemplates daily administration of the compound of Example 1 to sexually mature male cynomolgus monkeys until sperm counts per ejaculation drop below 200 million sperm cells. Cynomolgus monkeys with 130 ± 70 million sperm per ejaculation are considered poor candidates for breeding programs compared to the 734 ± 136 million sperm per ejaculation reported from successful breeders. Sperm counts were assessed weekly or biweekly on fresh semen samples obtained using electroejaculation. Three macaques were orally administered 2.5 mg / kg, which is the equivalent dose of 10 mg / kg in mice based on body surface area. Over the 54-day treatment period, individual sperm counts were 27, 175 and 31 × 10 6 Animals are currently recovering to assess reversibility (data not shown). A second cohort of three male cynomolgus monkeys was administered 5 mg / kg / day of the compound of Example 1 for 30 days, followed by 7.5 mg / kg / day for one week. Initial individual sperm counts of 598, 203 and 277×10 6 After 14 days, the numbers were 377, 62, and 134 × 10 6 After 30 days of treatment with 5 mg / kg / day, the levels were 262, 28, and 70 × 10 6 After an additional week of treatment with 7.5 mg / kg / day, individual sperm counts were 132, 38, and 12×10 6 The results showed efficacy in all three animals. Since day 38, the animals have been in recovery to assess reversibility. Four weeks after the last dose, individual sperm counts were 297, 71, and 300 x 10 6 , with 50% reversibility in animal #1, 65% reversibility in animal #2, and 100% reversibility in animal #3.

[0201] Rat and Dog Studies: In a repeated dose toxicity study (see Example 22) in male Sprague-Dawley rats and male Beagle dogs, administration of various daily doses of the compound of Example 1 for 14 days resulted in histopathological degeneration of the germinal epithelium of the testes, an effect seen in all evaluated seminiferous tubules in dog testis slides and in a subset of evaluated seminiferous tubules in rat testis slides (Figure 11).

[0202] Example 20. Pharmacokinetic (PK) Study

[0203] Single-dose pharmacokinetic (PK) studies at therapeutic dose levels: provide area under the curve (AUC) values ​​to better compare exposure levels between species.

[0204] Mouse study: Fifteen sexually mature male CD-1 mice were administered a single dose of 10 mg / kg of the compound of Example 1, which showed contraceptive effects in early studies. 0-inf The AUC extrapolated to 100 mg / mL was 6,681 h*(ng / mL). This value served as the basis for calculating the fold-over efficacy across species.

[0205] NHP study: Three young adult male marmosets were administered a single dose of 5 mg / kg of the compound of Example 1, and three sexually mature male cynomolgus monkeys were administered a single dose of 0.5, 1, 5 and 10 mg / kg. Table 1 shows the plasma AUC 0-last Levels and fold relative to mouse exposure are shown. [Table 1]

[0206] Repeated dose PK study at supratherapeutic dose levels:

[0207] Rat study: Male Sprague-Dawley rats (7-9 weeks old) were dosed for 14 days with 0, 25, 50 and 125 mg / kg / day (3 rats per group) of the compound of Example 1. The dose was reduced to 75 mg / kg on the 7th day because 125 mg / kg / day was poorly tolerated.

[0208] In this study, the AUC from time 0 to the final concentration measurement time (48 hours) was measured (AUC 0-48 Table 2 shows the plasma AUC 0-48 Levels and fold relative to mouse exposure are shown. [Table 2]

[0209] Dog study: Two male beagle dogs (8-12 months old) were administered the compound of Example 1 at 0, 25 and 100 mg / kg / day for 14 days. In this study, the AUC 0-inf Table 3 shows the plasma AUC 0-last Levels and fold relative to mouse exposure are shown. [Table 3]

[0210] Example 21. In vitro testing Table 4 below summarizes the results of in vitro testing for the compound of Example 1. [Table 4-1] [Table 4-2]

[0211] Example 22. Toxicity test Single Dose Toxicity: The respective maximum tolerated doses (MTDs) of the compound of Example 1 in male CD-1 mice, Sprague-Dawley rats and beagle dogs were ≧1,000 mg / kg, ≧750 mg / kg and ≧500 mg / kg, which were the respective highest dose levels tested.

[0212] Therapeutic Repeat Dose Toxicity:

[0213] Mice: Forty sexually mature male CD-1 mice were dosed for four weeks with 7.5 and 10 mg / kg / day, respectively, of the compound of Example 1. All treated animals behaved normally, with no changes in body weight, CBC parameters, or clinical chemistry parameters compared to control animals.

[0214] Non-human primates: All six male cynomolgus monkeys in the efficacy study behaved normally, with no significant changes in body weight, CBC parameters, or clinical chemistry parameters.

[0215] Supratherapeutic repeated dose toxicity 14-day dose-ranging (DRF) study in rats: Male Sprague-Dawley rats (7-9 weeks old) were administered 0, 25, 50, 125 and 250 mg / kg / day (5 rats per group) of the compound of Example 1 by oral gavage. 25 and 50 mg / kg were well tolerated. An initial dose of 125 mg / kg was poorly tolerated and was reduced to 75 mg / kg for the remaining 8 days. During that period, the animals' overall health and activity improved, body weights increased, and CBC and clinical chemistry were normal. 250 mg / kg / day was not tolerated. These results indicate that the maximum tolerated dose over the 2-week treatment period was 50 mg / kg.

[0216] 14-day DRF study in dogs: Male beagle dogs (8-12 months old) were administered 0, 25, 50 and 100 mg / kg / day (2 per group) of the compound of Example 1 by oral gavage. 25 mg / kg was well tolerated, both animals behaved normally and showed no signs of toxicity. 50 mg / kg was not tolerated. In the 100 mg / kg group, one dog showed no signs of toxicity. The other dog lost weight from day 12 until termination. Based on these results, the maximum tolerated dose over the 2-week treatment period was 25 mg / kg.

[0217] Example 23. Synthesis of 4-(5-(4-(4-fluorophenyl)-2,2-dimethyl-2H-chromen-6-yl)-1H-pyrrol-2-yl)benzoic acid. [ka]

[0218] a. Preparation of tert-butyl 2-(4-(methoxycarbonyl)phenyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrole-1-carboxylate. [ka]

[0219] Under nitrogen atmosphere, (Boc)2O (20.0 mL, 1 M in DCM, 2.1 equiv.) was added to a solution of methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrol-2-yl)benzoate (3.20 g, 9.72 mmol, 1.0 equiv.) and DMAP (60 mg, 0.49 mmol, 0.05 equiv.) in dry MeCN (5 mL) at room temperature. The mixture was stirred until the starting material was completely consumed. After adding water, the resulting mixture was extracted with DCM (20 mL x 3). The organic phase was washed with brine, dried over Na2SO4, and evaporated under reduced pressure. The residue was purified by flash column chromatography (SiO2, 100% hexane to 10% EtOAc in hexane) to give the product (2.34 g, 56%) as a colorless oil. 1 H NMR(400 MHz,CDCl3)δ 8.04-7.97(m,2H),7.40-7.34(m,2H),6.64(d,J=3.3 Hz,1H),6.25(d,J=3.3 Hz,1H),3.92(s,3H),1.35(s,12H),1.32(s,9H).

[0220] b. Preparation of tert-butyl 2-(2,2-dimethyl-4-oxochroman-6-yl)-5-(4-(methoxy-carbonyl)phenyl)-1H-pyrrole-1-carboxylate. [ka]

[0221] 6-Bromo-2,2-dimethylchroman-4-one (550 g, 2.16 mmol, 1.1 equiv), tert-butyl 2-(4-(methoxycarbonyl)phenyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrole-1-carboxylate (822 mg, 1.92 mmol, 1.0 equiv), K2CO3 (830 mg, 6.01 mmol, 3.1 equiv) were taken in a round bottom flask followed by DME (15 mL) and H2O (2 mL). N2 was then bubbled through the reaction mixture for 10 min followed by the addition of Pd(dppf)Cl2.CH2Cl2 (160 mg, 0.196 mmol, 0.1 equiv). The vial was then sealed and placed in a preheated oil bath at 90 °C and refluxed for 6 h. After completion of the reaction, the reaction mixture was added with brine, extracted with EtOAc (20 mL×3), and dried over MgSO4. The solvent was evaporated to dryness. The residue was purified by flash column chromatography (SiO2, 100% hexane to 20% EtOAc in hexane) to give the product as a white solid (600 mg, 66%). 1 H NMR(400 MHz,CDCl3)δ 8.08-8.01(m,2H),7.88(d,J=2.3 Hz,1H),7.53(dd,J=8.5,2.3 Hz,1H),7.48-7.41(m,2H),7.03-6.92(m,1H),6.30(d,J=3.4 Hz,1H),6.23(d,J=3.4 Hz,1H),3.93(s,3H),2.74(s,2H),1.48(s,6H),1.19(s,9H).

[0222] c. Preparation of tert-butyl 2-(2,2-dimethyl-4-(((trifluoromethyl)sulfonyl)oxy)-2H-chromen-6-yl)-5-(4-(methoxycarbonyl)phenyl)-1H-pyrrole-1-carboxylate. [ka]

[0223] To a stirred solution of tert-butyl 2-(2,2-dimethyl-4-oxochroman-6-yl)-5-(4-(methoxycarbonyl)phenyl)-1H-pyrrole-1-carboxylate (583 mg, 1.23 mmol, 1.0 equiv), 2,6-lutidine (925 mg, 8.63 mmol, 7.0 equiv) and DMAP (41 mg, 0.34 mmol, 0.3 equiv) in anhydrous DCM (10 mL) was added anhydrous triflic (1.00 g, 3.54 mmol, 2.9 equiv) dropwise at 0° C. and the reaction mixture was allowed to warm to room temperature slowly with stirring. After stirring at room temperature overnight, the reaction was quenched with saturated sodium bicarbonate solution and extracted with DCM (20 mL×3). The combined organic layers were then washed with brine, dried over MgSO4, filtered and concentrated under reduced pressure to give a crude brown oil. The crude product was purified by flash column chromatography (SiO 2 , 100% hexanes to 10% EtOAc in hexanes) to give the product (550 mg, 77%) as a colorless liquid. 1 H NMR(400 MHz,CDCl3)δ 8.09-8.02(m,2H),7.50-7.42(m,2H),7.32-7.23(m,2H),6.86(d,J=8.9 Hz,1H),6.31(d,J=3.4 Hz,1H),6.21(d,J=3.4 Hz,1H),5.66(s,1H),3.93(s,3H),1.55(s,6H),1.19(s,9H).

[0224] d. Preparation of tert-butyl 2-(4-fluorophenyl)-2,2-dimethyl-2H-chromen-6-yl)-5-(4-(methoxycarbonyl)phenyl)-1H-pyrrole-1-carboxylate. [ka]

[0225] tert-Butyl 2-(2,2-dimethyl-4-(((trifluoromethyl)sulfonyl)oxy)-2H-chromen-6-yl)-5-(4-(methoxycarbonyl)phenyl)-1H-pyrrole-1-carboxylate (200 g, 0.329 mmol, 1 equiv), (4-fluorophenyl)boronic acid (68 mg, 0.49 mmol, 1.5 equiv), K3PO4 (4.0 mL in HO, 0.5 M, 2.0 mmol, 6.1 equiv) were placed in a round bottom flask and then THF (2 mL) was added. The reaction mixture was then sparged with N2 for 10 min followed by the addition of XPhos Pd G2 (60 mg, 0.076 mmol, 0.2 equiv). The vial was then sealed and placed in a preheated block at 45 °C and stirred for 3 h. After completion of the reaction, the reaction mixture was added with brine, extracted with EtOAc (5 mL×3), dried over MgSO4, and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography (SiO2, 100% hexane to 20% EtOAc in hexane) to give the product as a white solid (132 mg, 72%). The residue was purified by flash column chromatography (SiO2, 100% hexane to 20% EtOAc in hexane) to give the product as a white solid (132 mg, 72%). 1 H NMR(400 MHz,CDCl3)δ 8.09-7.99(m,2H),7.45-7.38(m,2H),7.37-7.28(m,2H),7.21(dd,J=8.3,2.2 Hz,1H),7.13-7.02(m,2H),7.01(d,J=2.1 Hz,1H),6.91(d,J=8.3 Hz,1H),6.27(d,J=3.4 Hz,1H),6.14(d,J=3.4 Hz,1H),5.62(s,1H),3.93(s,3H),1.52(s,6H),1.16(s,9H).

[0226] e. Preparation of methyl 4-(5-(4-(4-fluorophenyl)-2,2-dimethyl-2H-chromen-6-yl)-1H-pyrrol-2-yl)benzoate. [ka]

[0227] tert-Butyl 2-(4-(4-fluorophenyl)-2,2-dimethyl-2H-chromen-6-yl)-5-(4-(methoxycarbonyl)phenyl)-1H-pyrrole-1-carboxylate (100 mg, 0.181 mmol, 1 equiv.) was heated to 180° C. under N2 gas for 30 min. The dark residue was purified by flash column chromatography to give the product (62 mg, 76%) as a white powder. 1 H NMR(400 MHz,CDCl3)δ 8.52(s,1H),8.03(d,J=8.0 Hz,2H),7.52(d,J=8.1 Hz,2H),7.38(td,J=5.4,2.3 Hz,3H),7.18-7.10(m,3H),6.96(d,J=8.3 Hz,1H),6.67(t,J=3.2 Hz,1H),6.39(t,J=3.2 Hz,1H),5.67(s,1H),3.93(s,3H),1.54(s,6H).

[0228] f. Preparation of 4-(5-(4-(4-fluorophenyl)-2,2-dimethyl-2H-chromen-6-yl)-1H-pyrrol-2-yl)benzoic acid. [ka]

[0229] To a solution of methyl 4-(5-(4-(4-fluorophenyl)-2,2-dimethyl-2H-chromen-6-yl)-1H-pyrrol-2-yl)benzoate (50 mg, 0.11 mmol, 1.0 equiv.) in THF (1 mL) and MeOH (1 mL) was added LiOH (50 mg, 1.2 mmol, 11 equiv.) dissolved in water (1 mL), and the resulting mixture was stirred at room temperature overnight. The organic layer was then evaporated under reduced pressure, and the aqueous suspension was acidified to pH 1.0 with 2N HCl. The reaction mixture was then extracted with EtOAc (2 mL×3), washed with brine, and dried over MgSO4. The extract was purified by flash column chromatography (SiO2, 100% hexane to 50% EtOAc in hexane, 2% HCOOH) to give the product (36 mg, 74%) as a yellow solid. 1H NMR(400 MHz,THF-d8)δ 10.40(s,1H),7.96-7.89(m,2H),7.64-7.57(m,2H),7.50-7.36(m,3H),7.27(d,J=2.2 Hz,1H),7.21-7.12(m,2H),6.86(d,J=8.4 Hz,1H),6.60(dd,J=3.7,2.5 Hz,1H),6.27(dd,J=3.7,2.4 Hz,1H),5.72(s,1H),1.46(s,6H).

[0230] Example 24. Synthesis of Representative Compounds The following compounds were prepared using procedures similar to those described above: [ka] [ka]

[0231] Example 25. Biological activity Representative compounds of the present invention were evaluated in the assay described in Example 13 and the following data was obtained. [Table 11-1] [Table 11-2] [Table 11-3] [Table 11-4] [Table 11-5]

[0232] All publications, patents, and patent applications are incorporated herein by reference as if individually incorporated by reference. The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention.

Claims

1. Compounds of formula (I): 【Chemistry 50】 or a pharma- ceutically acceptable salt thereof, R １ is C １ -C ３ is alkyl, R ２ is C １ -C ３ is alkyl, R ３ is phenyl optionally substituted with one or more groups independently selected from C 1 -C 6 alkyl, which is optionally substituted with one or more groups independently selected from halo; R ４ is phenyl substituted with carboxy, optionally further substituted with one or more groups independently selected from C 1 -C 6 alkyl, optionally substituted with one or more groups independently selected from halo; R ５ is H, R ６ is H, or a pharma- ceutically acceptable salt thereof.

2. R １ 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein is methyl.

3. R ２ 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein is methyl.

4. R ３ 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein:

5. R ３ 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein is 4-methylphenyl.

6. R ４ 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein: is phenyl substituted with carboxy.

7. R ４ 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein is 4-carboxyphenyl. 【Request 8】 【Chemical 101】 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, selected from the group consisting of:

9. 【Chemical 51】 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, selected from the group consisting of:

10. 【Chemical 56】 2. The compound of claim 1 which is: or a pharma- ceutically acceptable salt thereof.

11. A pharmaceutical composition comprising a compound or a pharma- ceutically acceptable salt according to any one of claims 1 to 10, and a pharma- ceutically acceptable excipient.

12. A composition for use in medical treatment, comprising a compound or a pharma- ceutically acceptable salt according to any one of claims 1 to 10.

13. A composition for reducing sperm count in a male subject, comprising a compound or a pharma- ceutically acceptable salt according to any one of claims 1 to 10.

14. Use of a compound or a pharma- ceutically acceptable salt according to any one of claims 1 to 10 in the preparation of a medicament for reducing sperm count in a male subject.

15. A composition for producing reversible infertility in a male subject, comprising a compound or a pharma- ceutically acceptable salt according to any one of claims 1 to 10.

16. 11. A composition for reducing fertility after sexual intercourse between a male subject and a female subject, comprising a compound or a pharma- ceutically acceptable salt according to any one of claims 1 to 10.

17. A composition for selectively antagonizing RARα over RARβ and RARγ in vitro, comprising a compound or a pharma- ceutically acceptable salt thereof according to any one of claims 1 to 10.

18. 13. Use of a compound according to any one of claims 1 to 10, or a pharma- ceutically acceptable salt thereof, in the preparation of a medicament for treating a disease or condition associated with RARα activity in a subject.

19. A composition for treating a disease or condition associated with RARα activity in a subject, comprising a compound or a pharma- ceutically acceptable salt according to any one of claims 1 to 10.

Images